{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\pandas\\compat\\_optional.py:138: UserWarning: Pandas requires version '2.7.0' or newer of 'numexpr' (version '2.6.9' currently installed).\n",
      "  warnings.warn(msg, UserWarning)\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py:37: DeprecationWarning: distutils Version classes are deprecated. Use packaging.version instead.\n",
      "  LARGE_SPARSE_SUPPORTED = LooseVersion(scipy_version) >= '0.14.0'\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\feature_extraction\\image.py:167: DeprecationWarning: `np.int` is a deprecated alias for the builtin `int`. To silence this warning, use `int` by itself. Doing this will not modify any behavior and is safe. When replacing `np.int`, you may wish to use e.g. `np.int64` or `np.int32` to specify the precision. If you wish to review your current use, check the release note link for additional information.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  dtype=np.int):\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:35: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:597: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps, copy_X=True, fit_path=True,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:836: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps, copy_X=True, fit_path=True,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:862: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps, positive=False):\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:1097: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  max_n_alphas=1000, n_jobs=None, eps=np.finfo(np.float).eps,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:1344: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  max_n_alphas=1000, n_jobs=None, eps=np.finfo(np.float).eps,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\least_angle.py:1480: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps, copy_X=True, positive=False):\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\randomized_l1.py:152: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  precompute=False, eps=np.finfo(np.float).eps,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\randomized_l1.py:320: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=np.finfo(np.float).eps, random_state=None,\n",
      "C:\\Anaconda3\\lib\\site-packages\\sklearn\\linear_model\\randomized_l1.py:580: DeprecationWarning: `np.float` is a deprecated alias for the builtin `float`. To silence this warning, use `float` by itself. Doing this will not modify any behavior and is safe. If you specifically wanted the numpy scalar type, use `np.float64` here.\n",
      "Deprecated in NumPy 1.20; for more details and guidance: https://numpy.org/devdocs/release/1.20.0-notes.html#deprecations\n",
      "  eps=4 * np.finfo(np.float).eps, n_jobs=None,\n"
     ]
    }
   ],
   "source": [
    "import pdfplumber\n",
    "import PyPDF2\n",
    "import re\n",
    "import spacy\n",
    "from PyPDF2 import PdfReader\n",
    "import pandas as pd\n",
    "import nltk\n",
    "import pickle\n",
    "\n",
    "from nltk.tokenize import sent_tokenize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from nltk.stem import WordNetLemmatizer\n",
    " \n",
    "lemmatizer = WordNetLemmatizer()\n",
    "\n",
    "# df['lem_word']=[lemmatizer.lemmatize(word.lower()) for word in df['key']]\n",
    "# df['lem_word'] = df['lem_word'].apply(lambda x: x.strip())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_df = pd.read_excel('TRAINING_DATA.xlsx')\n",
    "t=train_df.apply(tuple, axis=1)\n",
    "out = list(map(eval, train_df['entity']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "training_data=[]\n",
    "for i in range(len(train_df)):\n",
    "    training_data.append((train_df['Train_data'][i],out[i]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('analysis and summary 6.1 .', {'entities': [(13, 20, 'R_T')]}),\n",
       " ('proportion of subject who develop fviii inhibitor \\uf0b7 subject withfviii inhibitor confirmed by the central laboratory a a titer ≥0.6bu/mlat baseline ( ie , no longer at risk for inhibitor ) will not be included.\\uf0b7 the number of subject who develop inhibitor ( numerator ) will include all subject where the blood sample collection for positive inhibitor occurred after the first dose of study drug , regardless of how many on-study ed had accrued at the time of sample collection .',\n",
       "  {'entities': [(310, 316, 'R_T')]}),\n",
       " ('\\uf0b7 the analysis will consist of the following descriptive statistic : numberof non- missingobservations , frequency and observed proportion of subject for which fviii inhibitor were detected at visit 4 .',\n",
       "  {'entities': [(105, 114, 'R_T'), (57, 66, 'R_T')]}),\n",
       " ('a two-sided 90 % ci for the corresponding proportion will be computed using the exact method ( section5.2.1 ) .',\n",
       "  {'entities': [(17, 19, 'R_T')]}),\n",
       " ('annualized bleeding rate during prophylaxis \\uf0b7 the analysis will consist of the following descriptive statistic : mean , standard deviation , median , minimum , and maximum observedabr , a well a the number of non-missing observation ( section5.2.2 ) .',\n",
       "  {'entities': [(141, 147, 'R_T'),\n",
       "    (150, 157, 'R_T'),\n",
       "    (164, 171, 'R_T'),\n",
       "    (120, 138, 'R_T'),\n",
       "    (113, 117, 'R_T'),\n",
       "    (101, 110, 'R_T')]}),\n",
       " ('\\uf0b7 additionally , abrs will be summarized by bleed type ( eg , spontaneousor traumatic ) and by bleed location ( eg , joint , soft tissue/muscle ) .',\n",
       "  {'entities': [(30, 40, 'R_T')]}),\n",
       " ('annualized total factor consumption of moroctocog alfa ( af-cc ) \\uf0b7 the analysis of annualized tfc and dose by weight ( iu/kg ) will consist of the following descriptive statistic : mean , standard deviation , median , minimum , and maximumobservedannualized tfc , a well a the number of non-missing observation ( section5.2.2 ) .summary table by reason for infusion will also be presented .',\n",
       "  {'entities': [(110, 116, 'R_T'),\n",
       "    (209, 215, 'R_T'),\n",
       "    (169, 178, 'R_T'),\n",
       "    (181, 185, 'R_T'),\n",
       "    (329, 342, 'R_T'),\n",
       "    (188, 206, 'R_T'),\n",
       "    (218, 225, 'R_T')]}),\n",
       " ('number of moroctocog alfa ( af-cc ) infusion used to treat each bleed \\uf0b7 summary statistic will be reported using the number of infusion a a continuous variable , and will include the mean , standard deviation , median , minimum , and maximum of the observed number of infusion ( section5.2.2 ) .',\n",
       "  {'entities': [(220, 227, 'R_T'),\n",
       "    (183, 187, 'R_T'),\n",
       "    (80, 89, 'R_T'),\n",
       "    (190, 208, 'R_T'),\n",
       "    (211, 217, 'R_T'),\n",
       "    (72, 79, 'R_T'),\n",
       "    (140, 159, 'R_T'),\n",
       "    (234, 241, 'R_T'),\n",
       "    (98, 106, 'R_T')]}),\n",
       " ('additionally , this endpoint will be summarized a a categorical variablewith category 1 , 2 , 3 , 4 , or > 4infusions needed to treat the blead ( section 5.2.3 ) .',\n",
       "  {'entities': [(37, 47, 'R_T')]}),\n",
       " ('frequency table will be provided , in which the numerator used for the computation of proportion will be the number of bleeds falling into each category and the denominator will be the total number of new bleeds across all subject .',\n",
       "  {'entities': [(0, 15, 'R_T')]}),\n",
       " ('the number of subject contributing data ( ie , the number of subject with any new bleed ) for the analysis will also be reported .',\n",
       "  {'entities': [(120, 128, 'R_T')]}),\n",
       " ('baseline summary descriptive statistic will be used to summarize the following variable : sex , age ( year at screening visit –birth year ) , age group ( pediatric : 12 to < 18 year and adult : 18 to ≤65 year ) , race , ethnicity , hemophilia a history , and medical history .',\n",
       "  {'entities': [(0, 38, 'R_T'), (55, 64, 'R_T'), (79, 87, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study treatmentexposure infusion data will be listed for each subject.a summary of moroctocog alfa ( af-cc ) consumption , by primary reason for infusion and across all reason , will include summary statistic on total unit ( iu ) per subject ( tfc ) , range of infusion ( iu ) ( minimum , maximum ) , dose ( iu ) per infusion , number of infusion per subject , and ed on studyper subject .',\n",
       "  {'entities': [(279, 286, 'R_T'),\n",
       "    (46, 52, 'R_L'),\n",
       "    (72, 79, 'R_T'),\n",
       "    (199, 208, 'R_T'),\n",
       "    (252, 257, 'R_T'),\n",
       "    (289, 296, 'R_T')]}),\n",
       " ('concomitant medication and nondrug treatment descriptive summary of concomitant medication and treatment will be reported .',\n",
       "  {'entities': [(57, 64, 'R_T'), (113, 121, 'R_T')]}),\n",
       " ('summary table will include all drug and nondrug treatment taken during the effective duration of study treatment , whether or not they were recorded at baseline .',\n",
       "  {'entities': [(0, 13, 'R_T')]}),\n",
       " ('safety summary and analysis all safety summary and analysis will be performed using the safety analysis set .',\n",
       "  {'entities': [(7, 14, 'R_T')]}),\n",
       " ('adverse event the number ( % ) of subject who experienced teaes will be reviewed and summarized by relatedness to the study drug and by maximum severity grade .',\n",
       "  {'entities': [(136, 143, 'R_T'), (85, 95, 'R_T')]}),\n",
       " ('descriptive statistic ( number and frequency ) will be provided for all adverse event summary .',\n",
       "  {'entities': [(86, 93, 'R_T'), (35, 44, 'R_T'), (12, 21, 'R_T')]}),\n",
       " ('no hypothesis testing will be carried out.adverse event reporting detail have been described in the protocol section 8 .',\n",
       "  {'entities': [(3, 21, 'R_T')]}),\n",
       " ('laboratory data additional laboratory test other thanassessment for factor viii inhibitor antibody will be presented in a summary table for all subject including sample size , mean , standard deviation , median , minimum , and maximum .',\n",
       "  {'entities': [(176, 180, 'R_T'),\n",
       "    (122, 135, 'R_T'),\n",
       "    (227, 234, 'R_T'),\n",
       "    (213, 220, 'R_T'),\n",
       "    (162, 173, 'R_T'),\n",
       "    (204, 210, 'R_T'),\n",
       "    (183, 201, 'R_T')]}),\n",
       " ('vital sign and physical examination descriptive statisticsofobservedvalues and change from baseline for vital sign at each visit , including height ( cm ) , weight ( kg ) , blood pressure ( mmhg ) , heart rate ( beats/min ) , and body temperature ( °f ) , a well asabnormal finding from physical examination , will be presented.7 .',\n",
       "  {'entities': [(27, 30, 'R_T'), (157, 163, 'R_T')]}),\n",
       " ('analysis and summary 6.1 .', {'entities': [(13, 20, 'R_T')]}),\n",
       " ('\\uf0b7 analysis methodology : \\uf0b7 time to first occurrence of adjudicated 3-point macewill be analyzed using a cph model adjusting for treatment group ( categorical , pooled lotiglipron v placebo ) with baseline sglt2i use ( y/n ) a the stratification factor ( section 5.2.4 ) .',\n",
       "  {'entities': [(230, 244, 'R_T'), (3, 4, 'R_T')]}),\n",
       " ('\\uf0b7 km curve will be generated to demonstrateincidence of adjudicated 3-point maceover time by treatment group ( pooled lotiglipron v placebo ) .',\n",
       "  {'entities': [(2, 10, 'R_F')]}),\n",
       " ('missing data will not be imputed explicitly due to the censoring at random assumption inherent in the cph model.\\uf0b7 the sample size , number of event , study exposureand hazard rate will be presented for each treatment group .',\n",
       "  {'entities': [(118, 129, 'R_T')]}),\n",
       " ('\\uf0b7 the estimated hazard ratio ( hr ) , 95 % confidence interval and p-valuefor hr comparing lotiglipron to placebowill be presented .',\n",
       "  {'entities': [(43, 62, 'R_T'), (23, 28, 'R_T')]}),\n",
       " ('\\uf0b7 the above cph analysis and km curve will be repeated without pooling lotiglipron treatment group and the resultingstatistics comparing lotiglipron to placebo will be presented in the same table/figureoutput but treated a nominal .',\n",
       "  {'entities': [(29, 37, 'R_F'), (190, 195, 'R_T')]}),\n",
       " ('then each of the 100 complete datasets will be analyzed using a cph model and finally all 100 result will be combined into a single estimate ( section 5.3.1 ) .',\n",
       "  {'entities': [(132, 140, 'R_T')]}),\n",
       " ('the estimatedhr comparing pooled lotiglipron to placebo , along with 95 % ci , p-value will be reported .',\n",
       "  {'entities': [(69, 76, 'R_T'), (95, 103, 'R_T'), (79, 86, 'R_T')]}),\n",
       " ('\\uf0b7 the tipping point analysis ( section 5.3.1 ) will first impute the missing data based on all observed time to event/censoring data in the pooled lotiglipron groupunder the car/mar assumption ( ie , is defined a the hazard ratio comparing missing data to observed data in the same treatment group , with corresponding to the car assumption ) , and thenin the_x0000_ direction towards a more and more conservative mnar assumption ( ie , by gradually increasing ) , the tip_x0000_p=ing1 point will be identified a the smallest ( ) that overturn the conclusion of significance.p-values corresponding to each of this line search will be tabul_x0000_atedand the tipping point if identifiable will be called ou_x0000_t in_x0000_ th > e 1output .',\n",
       "  {'entities': [(224, 229, 'R_T'), (550, 562, 'R_T')]}),\n",
       " ('the same statistic will be reported a described for the main analysis .',\n",
       "  {'entities': [(27, 35, 'R_T'), (9, 18, 'R_T')]}),\n",
       " ('safety endpoint based on the safety analysis set , number ( n ) , percent ( % ) of participant and total number of occurrence of aes with the following will be summarized by treatment groupwith or without pooling lotiglipron treatment group : \\uf0b7 teaes \\uf0b7 saes \\uf0b7 ae leading to permanent discontinuation from study intervention or study \\uf0b7 hypoglycemia ( 3 level according to table 2 ) \\uf0b7 aesis \\uf0b7 clinical laboratory abnormality they will be summarized using the on-study approach a defined in section 3.5.1.the on- treatment+28-day approach will only be presented a a flag in listing .',\n",
       "  {'entities': [(571, 578, 'R_L'),\n",
       "    (8, 9, 'R_T'),\n",
       "    (160, 170, 'R_T'),\n",
       "    (371, 376, 'R_T')]}),\n",
       " ('\\uf0b7 the sample size , mean , standard deviation , median , minimum , and maximum atthe baseline and post-baseline visit ( converted to year from the first dose ) for observed egfr value and change from baseline will be presented for each treatment group .',\n",
       "  {'entities': [(71, 78, 'R_T'),\n",
       "    (20, 24, 'R_T'),\n",
       "    (57, 64, 'R_T'),\n",
       "    (48, 54, 'R_T'),\n",
       "    (27, 45, 'R_T'),\n",
       "    (6, 17, 'R_T')]}),\n",
       " ('\\uf0b7 given a visit ( converted to number of year from the first dose ) , the least-squares ( l ) mean , the 95 % confidence interval for the l mean , the difference in the l mean between lotiglipronand theplacebo , it corresponding 95 % confidence interval and p- value will be presented .',\n",
       "  {'entities': [(110, 129, 'R_T'), (94, 98, 'R_T')]}),\n",
       " ('in addition , the l mean of rate of change in egfr per year bytreatment group and the difference between lotiglipron and placebo along with 95 % ci and p-value will be presented .',\n",
       "  {'entities': [(140, 147, 'R_T'), (152, 159, 'R_T'), (20, 24, 'R_T')]}),\n",
       " ('\\uf0b7 l mean plot of change from baseline in egfr over time ( in year ) by treatment group will be generated .',\n",
       "  {'entities': [(4, 8, 'R_T'), (9, 13, 'R_F')]}),\n",
       " ('\\uf0b7 the above analysis and plot will be repeated without pooling lotiglipron treatment group and the resulted statistic comparing lotiglipron to placebo will be presented in the same table/figureoutput but treated a nominal .',\n",
       "  {'entities': [(181, 186, 'R_T'), (25, 29, 'R_F'), (108, 117, 'R_T')]}),\n",
       " ('each of the 100 complete datasets will then be analyzed using the linear mixed effect model a described in section 5.3.2and finallyall 100 result will be combined into a single estimate ( section 5.3.2 ) .',\n",
       "  {'entities': [(177, 185, 'R_T')]}),\n",
       " ('\\uf0b7 the sample size , mean , standard deviation , median , minimum , and maximum at the baseline and post-baseline visit ( converted to year from the first dose ) for observed egfr value and change from baseline will be presented for each treatment arm .',\n",
       "  {'entities': [(71, 78, 'R_T'),\n",
       "    (20, 24, 'R_T'),\n",
       "    (57, 64, 'R_T'),\n",
       "    (48, 54, 'R_T'),\n",
       "    (27, 45, 'R_T'),\n",
       "    (6, 17, 'R_T')]}),\n",
       " ('\\uf0b7 given a visit ( converted to number of year from the first dose ) , the least-squares ( l ) mean , the 95 % confidence interval for the l mean , the difference in the l mean between lotiglipronand theplacebo , it corresponding 95 % confidence interval and p- value will be presented .',\n",
       "  {'entities': [(110, 129, 'R_T'), (94, 98, 'R_T')]}),\n",
       " ('in addition , the l mean of rate of change in egfr per year by treatment group and the difference between lotiglipron and placebo along with 95 % ci and p-value will be presented .',\n",
       "  {'entities': [(153, 160, 'R_T'), (20, 24, 'R_T'), (141, 148, 'R_T')]}),\n",
       " ('\\uf0b7 time to first occurrence of hba1c < 7 % in the absence of weight gain orepisode of severe hae\\uf0b7 time to first occurrence of composite renal outcome \\uf0b7 time to first occurrence ofnew symptomatic lower extremity pad \\uf0b7 time to first occurrence ofmajor adverse composite event \\uf0b7 time to all-cause death 6.2.3 .',\n",
       "  {'entities': [(60, 66, 'R_T')]}),\n",
       " ('( percent ) change from baseline \\uf0b7 endpoint : \\uf0b7 change from baseline in hba1c at week 72 \\uf0b7 percent change from baseline in body weight at week 72 \\uf0b7 estimand strategy : on-treatment ( section 4 ) .',\n",
       "  {'entities': [(128, 134, 'R_T')]}),\n",
       " ('\\uf0b7 the sample size , mean , standard deviation , median , minimum , and maximum atthe baseline and post-baseline visit for observed value and change from baseline will be presented for each treatment group.given a visit , the least-squares ( l ) mean and standard errorby treatment group , the difference in the l mean between each lotigliprongroup and the placeboalong with95 % confidence interval and p-value will be presented .',\n",
       "  {'entities': [(71, 78, 'R_T'),\n",
       "    (6, 17, 'R_T'),\n",
       "    (20, 24, 'R_T'),\n",
       "    (57, 64, 'R_T'),\n",
       "    (402, 409, 'R_T'),\n",
       "    (48, 54, 'R_T'),\n",
       "    (27, 45, 'R_T'),\n",
       "    (378, 397, 'R_T')]}),\n",
       " ('\\uf0b7 proportion of hba1c < 7 % , < =6.5 % , < =5.6 % at week 72 \\uf0b7 proportion of body weight loss > =5 % , > =10 % , > =15 % , > =20 % at week 72 \\uf0b7 analysis set : mitt ( section 4 ) .',\n",
       "  {'entities': [(82, 88, 'R_T')]}),\n",
       " ('\\uf0b7 analysis methodology : the binary endpoint will be analyzed using logistic regression with missing dataimputed from mmrm model according to section 5.2.1.\\uf0b7 intercurrent event and missing data : all data collected after the last dose + 5days will be excluded .',\n",
       "  {'entities': [(68, 87, 'R_T')]}),\n",
       " ('\\uf0b7 the sample size , the number ( % ) of subject achieving the goal will be presented for each treatment group .',\n",
       "  {'entities': [(6, 17, 'R_T')]}),\n",
       " ('\\uf0b7 adjusted odds ratio ( or ) along with 95 % ci and p-values comparing each lotiglipron group toplacebo will be presented .',\n",
       "  {'entities': [(40, 47, 'R_T'), (11, 21, 'R_T')]}),\n",
       " ('time to event endpoint the following time to event endpoint will be analyzed using the same mainanalysis ofthe primary endpoint , a described insection 6.1.1.1 : time to first occurrence : \\uf0b7 mi \\uf0b7 ischemic stroke \\uf0b7 hemorrhagic stroke \\uf0b7 cv death \\uf0b7 hospitalization for unstable angina \\uf0b7 hospitalization for heart failure \\uf0b7 lower extremity tissue loss ( ischemic ulceration or gangrene ) \\uf0b7 lower extremity arterial revascularization procedure \\uf0b7 lower extremity amputation ( major or minor ) 6.3.2 .',\n",
       "  {'entities': [(235, 237, 'R_T')]}),\n",
       " ('continuous endpoint the following continuous endpoint will be analyzed using the same analysis a described in section 6.2.3 : \\uf0b7 change from baseline in the following parameter over time : o hba1c , fpg , fpi , homa2- % s , homa2- % b , uacr , egfr ( using ckd-epi- scr-scys combined ) o waist circumference , waist-to-hip ratio o sbp , dbp , and pulse rate \\uf0b7 percent change from baseline in the following parameter over time : o body weight o fasting direct hdl-c , direct ldl-c , triglyceride , total cholesterolo hscrp , il-6 , and fibrinogen 6.3.3 .',\n",
       "  {'entities': [(434, 440, 'R_T'), (166, 175, 'R_T'), (322, 327, 'R_T')]}),\n",
       " ('sf-36v2 health survey acute sf-36v2scorewill be summarized descriptivelyusing the fa , by domain , treatment group and visit .',\n",
       "  {'entities': [(48, 58, 'R_T')]}),\n",
       " ('the objective of such analysis , if conducted , would aim to explore the relationship between concentration of lotiglipron and effect on endpoint of interest and also identification of potential demographic determinant ( eg , age , sex , and weight ) influencing the observed pk and/or pd .',\n",
       "  {'entities': [(242, 248, 'R_T')]}),\n",
       " ('these analysis , if conducted , will be reported separately from the main csr .',\n",
       "  {'entities': [(40, 48, 'R_T')]}),\n",
       " ('the following subgroup will be analyzed : \\uf0b7 baseline sglt2i use ( y/n ) \\uf0b7 demographic ( age , sex , race , ethnicity , geographic region , bmi ) \\uf0b7 baseline hba1c ( < 7 % , 7-8.5 % , and > 8.5 % ) \\uf0b7 baseline egfr ( < =60 and > 60 ) ; \\uf0b7 baseline albuminuria ( < 30 mg/g , 30-300 mg/g , > 300 mg/g ) \\uf0b7 baseline ascvd ( cardiac [ yes or no ] , cerebral vessel disease [ yes or no ] , peripheral artery disease [ yes or no ] ) , chf of presumptive ischemic etiology [ yes or no ] , ckd [ yes or no ] ) \\uf0b7 baseline use of t2dm medication ( metformin or another biguanide [ yes or no ] , sulfonylurea [ yes or no ] , dppivi [ yes or no ] , sglt2i [ yes or no ] , insulin [ yes or no ] , other class ( -glucosidase inhibitor , meglitinide , ppar ) of agent [ yes or no ] ) _x0000_ _x0000_ \\uf0b7 baseline use of chronic cv medication including but not limited too bp lowering agent – -blockers , acei , arb , diuretic , loop diuretic , aldosterone receptor antagonist , other vasodilator ; _x0000_ o lipid modifying agent – statin , fibrates , other agent ; o agent to prevent blood clot –aspirin , p2y12 inhibitor , fxa inhibitor ; \\uf0b7 enrollment population ( the first 3900 v the last 5100 ) all randomized will be the analysis set for subgroup analysis .',\n",
       "  {'entities': [(11, 12, 'R_T'), (310, 312, 'R_T')]}),\n",
       " ('in each category , sample size , number of event , study exposureand hazard rate will be presented for each treatment group.hazard ratio comparing pooled lotiglipron to placeboalong with 95 % ciwill be generated .',\n",
       "  {'entities': [(19, 30, 'R_T'), (131, 136, 'R_T')]}),\n",
       " ('p-value of the interaction term will also be reported , to evaluate if there ’ s anytreatment effect modification.at least 30 event in any category of the subgroup are required in order to conduct the subgroup analysis [ 2 ] .the category with le than 30 event will be combined with other category or excluded from thesubgroup analysis .',\n",
       "  {'entities': [(0, 7, 'R_T'), (45, 53, 'R_T')]}),\n",
       " ('baseline summary demographic information including age ( year ) , categorical age , sex , race , ethnicity , weight ( kg ) , height ( m ) , bmi ( kg/m2 ) , geographic region will be summarized by treatment group .',\n",
       "  {'entities': [(109, 115, 'R_T'), (9, 16, 'R_T'), (182, 192, 'R_T')]}),\n",
       " ('baseline characteristic including baseline hba1c , fpg , egfr , albuminuria , lipid , blood pressure etc will be summarized by treatment group .',\n",
       "  {'entities': [(113, 123, 'R_T')]}),\n",
       " ('duration of t2dm , background aha therapy , baseline cv risk factor , renal risk factor , diabetes characteristic and otherfactors/conditions of interestwill be summarized by treatment group .',\n",
       "  {'entities': [(161, 171, 'R_T'), (53, 55, 'R_T')]}),\n",
       " ('study conduct and participantdisposition number of subject screened , randomized , discontinuing treatment and study , and retrieved dropout ( defined a subject whohave discontinued treatment but remain in the study ) will be tabulated by treatment group .',\n",
       "  {'entities': [(226, 235, 'R_T')]}),\n",
       " (\"study/treatment exposure extent of exposure to study intervention will be summarizedusingsummary statistic ( n , mean , median , standard deviation , and range ) and frequency n ( % ) for categorized '' number of week on treatment/study '' by treatment group.6.5.4 .\",\n",
       "  {'entities': [(97, 106, 'R_T'),\n",
       "    (120, 126, 'R_T'),\n",
       "    (129, 147, 'R_T'),\n",
       "    (13, 14, 'R_T'),\n",
       "    (113, 117, 'R_T'),\n",
       "    (166, 175, 'R_T'),\n",
       "    (154, 159, 'R_T')]}),\n",
       " ('concomitant medication and nondrug treatment subject takingspecificconcomitant medication ( not restricting to aha therapy , cv medication ) will be summarized at baseline and end of study , using the who-drug dictionary .',\n",
       "  {'entities': [(149, 159, 'R_T'), (125, 127, 'R_T')]}),\n",
       " ('safety summary and analysis all safety summaryand analysis will be based on the safety analysis set .',\n",
       "  {'entities': [(7, 14, 'R_T')]}),\n",
       " ('adverse event a 3-tier approach will be used to summarize teaes .',\n",
       "  {'entities': [(48, 57, 'R_T')]}),\n",
       " ('number ( % ) of subject with the ae and total number of episode of the aewill be reported by treatment group .',\n",
       "  {'entities': [(81, 92, 'R_T')]}),\n",
       " ('risk difference of pooled lotiglipronvs placebo will be primarily reported.to provide additional information , risk difference of each dose of lotiglipron v placebo will also be presented.all p-values reported for aes will not be adjusted for multiplicity .',\n",
       "  {'entities': [(201, 213, 'R_T'), (66, 74, 'R_T')]}),\n",
       " ('for tier 1 aes , incidence rate by treatment group , estimated risk differencecomparing lotiglipron to placebo along with 95 % confidence interval and p-value will be reported .',\n",
       "  {'entities': [(127, 146, 'R_T'), (151, 158, 'R_T'), (167, 175, 'R_T')]}),\n",
       " ('for tier 2 aes , in addition to point estimate of risk difference 95 % ci will be provided to help gauge the precision of the risk difference estimate .',\n",
       "  {'entities': [(66, 73, 'R_T'), (32, 46, 'R_T'), (109, 118, 'R_T')]}),\n",
       " ('they will not beidentified and reported separately but will be reported a part of the overall ae summary .',\n",
       "  {'entities': [(97, 104, 'R_T'), (31, 39, 'R_T')]}),\n",
       " ('aes will be displayed in alphabetical order of soc and ptand will be summarized using the “ on-study ” approacheas defined in section 3.5.1 .',\n",
       "  {'entities': [(69, 79, 'R_T')]}),\n",
       " ('the “ on-treatment+28-day ” approach will only be presented a a flag in listing .',\n",
       "  {'entities': [(72, 79, 'R_L')]}),\n",
       " ('severity and causality ( ie , all causality or treatment- related ) will be reported for aes where applicable .',\n",
       "  {'entities': [(76, 88, 'R_T')]}),\n",
       " ('a such , safety analysis is generally considered a an exploratory analysis and it purpose is to generate hypothesis for further investigation .',\n",
       "  {'entities': [(105, 115, 'R_T')]}),\n",
       " ('laboratory data laboratory test value for individual subject will be listed .',\n",
       "  {'entities': [(69, 75, 'R_L')]}),\n",
       " ('the observed laboratory value and change from baseline over time , shift in clinical laboratory test andsubjects with laboratory test abnormality will be summarized by treatment group .',\n",
       "  {'entities': [(154, 164, 'R_T')]}),\n",
       " ('all laboratory data listing and summary will be based onsafety analysis set using the on-treatment+5-day approach.clinical laboratory abnormality will be summarized with respect to prespecified criterion determined from normal range and abnormality cutoff considered to be clinically meaningful , following pfizer standards.specifically the following liver test abnormality will be reported : \\uf0b7 alt/ ast abnormality \\uf0b7 > uln \\uf0b7 > 2x uln \\uf0b7 > 3 x uln \\uf0b7 > 5 x uln \\uf0b7 > 8 x uln \\uf0b7 > 10 x uln \\uf0b7 > 20 x uln shift table will be generated for hba1c , fpg , alt , ast , amylase , lipase , uacr , sbp , dbp , heart rate , body weight , egfr , bun , serum creatinine using the worst on-treatment assessment approach .',\n",
       "  {'entities': [(32, 39, 'R_T'),\n",
       "    (382, 390, 'R_T'),\n",
       "    (154, 164, 'R_T'),\n",
       "    (613, 619, 'R_T'),\n",
       "    (503, 508, 'R_T'),\n",
       "    (20, 27, 'R_L'),\n",
       "    (227, 232, 'R_T')]}),\n",
       " ('vital sign descriptive statistic will be used to summarize seated blood pressure ( systolic and diastolic ) and seated pulse rate ( bpm ) by treatment group .',\n",
       "  {'entities': [(23, 32, 'R_T'), (49, 58, 'R_T')]}),\n",
       " ('electrocardiogram change from baseline for the ecg parameter hr , qtcf , pr interval , and qrs interval will be summarized by treatment and time .',\n",
       "  {'entities': [(51, 60, 'R_T'), (112, 122, 'R_T')]}),\n",
       " ('the frequency of uncorrected qt value above 500 m will be tabulated .',\n",
       "  {'entities': [(58, 67, 'R_T'), (4, 13, 'R_T')]}),\n",
       " ('the number ( % ) of participant with maximum postdose qtcf value and maximum increase from baseline in the following category will be tabulated by treatment : safety qtcfassessment degree of mild ( m ) moderate ( m ) severe ( m ) prolongation absolute value > 450-480 > 480-500 > 500 increase from baseline 30-60 > 607 .',\n",
       "  {'entities': [(134, 143, 'R_T'), (37, 44, 'R_T')]}),\n",
       " ('analysis and summary overview of analysis presentation : \\uf0b7 continuous data will be summarized using descriptive statistic ( mean , median , sd , minimum , maximum , and 2-sided 95 % ci ) \\uf0b7 categorical data ( including point estimate ) will be summarized by frequency count , percentage and binomial 95 % ci using the clopper-pearson method .',\n",
       "  {'entities': [(124, 128, 'R_T'),\n",
       "    (112, 121, 'R_T'),\n",
       "    (257, 272, 'R_T'),\n",
       "    (131, 137, 'R_T'),\n",
       "    (275, 285, 'R_T'),\n",
       "    (177, 184, 'R_T'),\n",
       "    (145, 152, 'R_T'),\n",
       "    (83, 93, 'R_T'),\n",
       "    (13, 20, 'R_T'),\n",
       "    (218, 232, 'R_T'),\n",
       "    (155, 162, 'R_T'),\n",
       "    (140, 142, 'R_T')]}),\n",
       " ('\\uf0b7 kaplan-meier estimate ( time-to-event distirbutions ) will be presented and displayed graphically where appropriate , together with a summary of associated statistic ( including hr , 2-sided 95 % ci , and 1-sided p-values ) .',\n",
       "  {'entities': [(88, 99, 'R_F'),\n",
       "    (151, 153, 'R_T'),\n",
       "    (136, 143, 'R_T'),\n",
       "    (193, 200, 'R_T'),\n",
       "    (158, 167, 'R_T'),\n",
       "    (15, 23, 'R_T')]}),\n",
       " ('table 4 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('a the targeted safety event defined above include some subjective criterion or multiple criterion occurring simultaneously , an assessment of whether or not event met the criterion of being target safety event requiring a reduction in the starting dose for part 2 will be made based on a review of individual patient data , summary of all aes , and exposure.6.1.2 .',\n",
       "  {'entities': [(324, 331, 'R_T')]}),\n",
       " ('secondary endpoint [ pharmacokinetics ] a record-level dataset pharmacokinetic analysis set -talazoparib will includeall talazoparib pk concentration that meet thecriteria below : \\uf0b7 pk sample collected at week1 \\uf0b7 pk sample collected at week 5 , 9 , 13 , and 17 at the same dose level without any dose modification for at least 14 day .',\n",
       "  {'entities': [(185, 191, 'R_T')]}),\n",
       " ('another record-level dataset pharmacokinetic analysis set -enzalutamidewill includeall enzalutamideconcentrationsthat meet the criterion below : \\uf0b7 pk sample collected at week 1 \\uf0b7 pk sample collected at week 5 , 9 , 13 , and 17 for patient who did not experience any dose reduction or interruption of enzalutamide .',\n",
       "  {'entities': [(150, 156, 'R_T')]}),\n",
       " ('pharmacokinetic analysis set –talazopariband pharmacokinetic analysis set – enzalutamide will be used for pk parameter derivation and summary table .',\n",
       "  {'entities': [(134, 147, 'R_T'), (109, 118, 'R_T')]}),\n",
       " ('additionally , blood sample for pk are collected at predoseand 2 hour postdoseat week 5 and predose at week 13 and 17 .',\n",
       "  {'entities': [(21, 27, 'R_T')]}),\n",
       " ('all planned individual patient ’ plasma concentration data will be listed ( pharmacokinetic population ) .',\n",
       "  {'entities': [(67, 73, 'R_L')]}),\n",
       " ('pk sample obtained beyond 10 % of the planned time will be included in the listing and could be included in the calculation of pk parameter ( based on discretion of the pharmacokineticist ) , however , will be removed from figure and table reporting mean concentration per planned sampling time .',\n",
       "  {'entities': [(223, 229, 'R_F'),\n",
       "    (130, 139, 'R_T'),\n",
       "    (3, 9, 'R_T'),\n",
       "    (250, 254, 'R_T'),\n",
       "    (75, 82, 'R_L'),\n",
       "    (234, 239, 'R_T')]}),\n",
       " ('in all data presentation ( except listing ) , value below the limit of the assay quantification ( blq ) will be set to zero .',\n",
       "  {'entities': [(34, 41, 'R_L')]}),\n",
       " ('in listing blq value will be reported a “ < llq ” , where llq will be replaced with the value for the lower limit of quantification .',\n",
       "  {'entities': [(3, 10, 'R_L'), (29, 37, 'R_T')]}),\n",
       " ('summarystatisticswill beprovidedforplasmaconcentrations of talazopariband enzalutamide and it n-desmethyl metabolite at scheduled visit by time point ( using the pk analysis set for talazoparib or enzalutamide , see section6.1.2 ) .',\n",
       "  {'entities': [(43, 44, 'R_T')]}),\n",
       " ('plasma concentration value below the limit of quantitation will be treated a zero in the descriptive statistic calculation .',\n",
       "  {'entities': [(101, 110, 'R_T')]}),\n",
       " ('zero concentration will be considered a missing in geometric mean calculation .',\n",
       "  {'entities': [(51, 65, 'R_T')]}),\n",
       " ('spaghetti plot of individual concentration against actual time postdose ( separate plot for each dose and scheduled visit ) will be presented .',\n",
       "  {'entities': [(10, 14, 'R_F')]}),\n",
       " ('pk parameter in estimating the pk parameter , blq value at the beginning of the profile will be set toare embedded between blqs , or quantifiable value occurring after two or more blqs , may be set to missing at the discretion of the pharmacokineticist .',\n",
       "  {'entities': [(3, 12, 'R_T')]}),\n",
       " ('if the actual time or dose time is missing , the scheduled time may be substituted in order to calculate the pk parameter .',\n",
       "  {'entities': [(112, 121, 'R_T')]}),\n",
       " ('a appropriate , additional pk parameter may be calculated and reported .',\n",
       "  {'entities': [(30, 39, 'R_T'), (47, 57, 'R_T'), (62, 70, 'R_T')]}),\n",
       " ('the following pk parameter of talazoparib and enzalutamide and it ndesmethyl metabolite will be summarized usingthe pharmacokinetic population ( specifically using the record-level set called pk analysis set –talazoparib and pk analysis set –enzalutamide ) a appropriate : c , c , t , auc , and cl /f will be summarized by dose and study visit .',\n",
       "  {'entities': [(96, 106, 'R_T'), (17, 26, 'R_T')]}),\n",
       " ('max trough max \\uf074 s dose-normalized auc , c , and c will be summarized by study visit .',\n",
       "  {'entities': [(59, 69, 'R_T'), (0, 3, 'R_T')]}),\n",
       " ('\\uf074 max trough the above mentioned pk parameter ( t excluded ) will be summarized by arithmetic max mean , standard deviation and cv , geometric mean , geometric cv , minimum , median , maximum value and the number of evaluable parameter .',\n",
       "  {'entities': [(175, 181, 'R_T'),\n",
       "    (165, 172, 'R_T'),\n",
       "    (98, 102, 'R_T'),\n",
       "    (69, 79, 'R_T'),\n",
       "    (184, 191, 'R_T'),\n",
       "    (128, 130, 'R_T'),\n",
       "    (133, 147, 'R_T'),\n",
       "    (2, 5, 'R_T'),\n",
       "    (36, 45, 'R_T'),\n",
       "    (105, 123, 'R_T')]}),\n",
       " ('the pk characteristic of t will max be described utilizing the number of observation , minimum , maximum and median .',\n",
       "  {'entities': [(87, 94, 'R_T'),\n",
       "    (109, 115, 'R_T'),\n",
       "    (97, 104, 'R_T'),\n",
       "    (32, 35, 'R_T')]}),\n",
       " ('geometric cv % is defined a sqrt ( exp ( variance of log transformed data ) -1 ) * 100 in addition , box and whisker plot for individual patient parameter auc , c , and c \\uf074 max trough by dose and scheduled visit a well a for dose-normalized auc , c , and c by \\uf074 max trough scheduled visit maybe be presented and overlaid with geometric mean .',\n",
       "  {'entities': [(173, 176, 'R_T'),\n",
       "    (10, 12, 'R_T'),\n",
       "    (145, 154, 'R_T'),\n",
       "    (101, 121, 'R_F'),\n",
       "    (41, 49, 'R_T'),\n",
       "    (326, 340, 'R_T')]}),\n",
       " ('however , separate summary of pk parameter including auc , c , and c by dose level and scheduled \\uf074 max trough visit in addition to summary of dose-normalized auc , c , and c by scheduled visit \\uf074 max trough will be generated for patient in part 1 .',\n",
       "  {'entities': [(99, 102, 'R_T'), (19, 26, 'R_T'), (33, 42, 'R_T')]}),\n",
       " ('exploratory endpoint for ctc count , a summary of the mean ( standard deviation ) , median , and range of baseline and postbaselinevalues will be provided for patient in part 1 ctc evaluable population .',\n",
       "  {'entities': [(39, 46, 'R_T'),\n",
       "    (54, 58, 'R_T'),\n",
       "    (84, 90, 'R_T'),\n",
       "    (97, 102, 'R_T'),\n",
       "    (61, 79, 'R_T')]}),\n",
       " ('in addition , the number and percentage of patient with ctc count ≥ 5vs .',\n",
       "  {'entities': [(18, 39, 'R_T')]}),\n",
       " ('the proportion of patient withsuch a conversion will be calculated along with the two-sided 95 % ci using clopper-pearson method ( exact methodfor a binomial proportion ) .',\n",
       "  {'entities': [(92, 99, 'R_T'), (56, 66, 'R_T')]}),\n",
       " ('the proportion of patient with sucha conversionwill be calculated along with the two-sided 95 % ciusing clopper-pearson method.the analysis of the proportion of patient with baseline ctc < 5 who show increased ctc postbaselinewill excludepatients with a ctc count of ≥ 5 per 7.5 ml of blood at baseline .',\n",
       "  {'entities': [(55, 65, 'R_T')]}),\n",
       " ('the proportion of patient with such a conversion will be calculated along with the two-sided 95 % ci using the clopper-pearson method .',\n",
       "  {'entities': [(93, 100, 'R_T'), (57, 67, 'R_T')]}),\n",
       " ('although not specifically listed a exploratory objective , analysis of efficacy including rpfs , orr in patient with soft tissue measurable disease at baseline , psa response , and time to psa progression may be evaluated during the course of the study and will be reported at the time of the final analysis of rpfs in all-comers , if not sooner .',\n",
       "  {'entities': [(26, 32, 'R_L'), (265, 273, 'R_T')]}),\n",
       " ('summary will be descriptive and not inferential .',\n",
       "  {'entities': [(0, 7, 'R_T')]}),\n",
       " ('specifically summary of time to event endpoint will be limitedto median and rate at specific timepoints of interest .',\n",
       "  {'entities': [(65, 71, 'R_T'), (13, 20, 'R_T')]}),\n",
       " ('summary of response rate will include number and percentage .',\n",
       "  {'entities': [(0, 7, 'R_T'), (38, 59, 'R_T')]}),\n",
       " ('summary will be provided regardless of mutation status or starting dose .',\n",
       "  {'entities': [(0, 7, 'R_T')]}),\n",
       " ('mutation status ( where available ) and starting dosewill be provided in data listing .',\n",
       "  {'entities': [(78, 85, 'R_L')]}),\n",
       " ('rpfs is defined a the time from the date of randomization to first objective evidence of radiographic progression a assessed in soft tissue per recist1.1 or in bone ( upon subsequent confirmation ) per pcwg3 guideline , or deathdue to any cause , whichever occurs first , and will be summarized in month using the following calculation : rpfs ( month ) = [ date of event/censoring –randomization date +1 ] /30.4375 .',\n",
       "  {'entities': [(44, 57, 'R_T'), (284, 294, 'R_T')]}),\n",
       " ('the documentationrequiredfor the determination of radiographic progressionis shown in table 5 .',\n",
       "  {'entities': [(86, 91, 'R_T')]}),\n",
       " ('table 5 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('criterion for evidence of radiographic progression date criterion for progression criterion for confirmation criterion for progression of progression documentation of disease detected ( requirement and timing ) progression on ( visit ) [ 1 ] confirmatory scan week9 bone lesion : 2or more new timing : at least 6weeks persistence of at least 2 lesion compared to baseline after progression identified lesion seen at week 9 bone scan by pcwg3 or at week17 visit [ 2 ] and 2 or more new bone lesion on bone scan ( compared to week9 scan ) table 5 .',\n",
       "  {'entities': [(537, 542, 'R_T')]}),\n",
       " ('criterion for evidence of radiographic progression date criterion for progression criterion for confirmation criterion for progression of progression documentation of disease detected ( requirement and timing ) progression on ( visit ) [ 1 ] confirmatory scan soft tissue lesion : no confirmatory scan not applicable progressive disease on ct or required for soft tissue mri by recist1.1 disease progression week17 or bone lesion : 2 or more new timing : at least 6weeks persistent of at least 2 of later lesion on bone scan after progression identified the lesion identified a compared to week9 bone required for bone lesion new compared to week 9 scan observed on bone scan [ 2 ] soft tissue lesion : no confirmatory scan not applicable progressive disease on ct or required for soft tissue mri by recist1.1 disease progression [ 1 ] progression detected by bone scan at an unscheduled visit prior to week 13 will requireconfirmation at least 6 week later following the confirmation criterion outlined in the table for week 9 .',\n",
       "  {'entities': [(1011, 1016, 'R_T')]}),\n",
       " ('if a patient ha a curative radiotherapy where the treatment intent is specified a ‘ primary treatment ’ or surgery where the treatment intent is specified a ‘ curative in intent ’ and the surgery outcome is either ‘ resected ’ or ‘ partially resected ’ prior to radiographic progression or death , the patient will also be censored on the date of the last adequate tumor assessment before the radiotherapy or surgery.two or more missed assessment is defined a follows : \\uf0b7 if the last adequate tumor assessment prior to the event occurs on or before 70 day from randomization , more than 119 day from that assessment ( two 8-week assessment plus a 7-day assessment window ) to the event ; \\uf0b7 if the last adequate tumor assessment prior to the event occurs after 70 day and on or before 126days from randomization , more than 147days from that assessment ( an8-week assessment plus a 12-week assessment plus a 7-day assessment window ) to the event ; \\uf0b7 if the last adequate tumor assessment prior to the event occurs after 126days from randomization , more than 175 day from that assessment ( two 12-week assessment plus a 7-day assessment window ) to the event .',\n",
       "  {'entities': [(561, 574, 'R_T')]}),\n",
       " ('the stratified analysis will be based on the following randomization stratification factor : previous treatment with any nht or taxane-based chemotherapy for cspc ( yes vs. no ) ; ddr mutational status ( deficient vs. non-deficient/unknown ) .',\n",
       "  {'entities': [(69, 83, 'R_T'), (55, 68, 'R_T')]}),\n",
       " ('the primary stratified analysis will be based on the stratification information recorded in iwrs .',\n",
       "  {'entities': [(53, 67, 'R_T')]}),\n",
       " ('prior to protocol amendment 6 , ddr mutational status for randomization/stratification wa obtained from tumor tissue ( archival or fresh biopsy ) or historical test result ( prior tumor tissue analysis using foundationone test ) .',\n",
       "  {'entities': [(72, 86, 'R_T'), (58, 71, 'R_T')]}),\n",
       " ('starting with protocol amendment 6 , ddr mutational status for randomization stratification wa derived from either tumor tissue ( archival slide or fresh biopsy or historical test result ) or peripheral blood ( liquid biopsy ) prior to randomization .',\n",
       "  {'entities': [(77, 91, 'R_T'), (63, 76, 'R_T')]}),\n",
       " ('if prospective result from bloodand tumor tissue sample are both available , apositive result from eitherwill be considered prospectively ddr-deficient for randomizationstratification .',\n",
       "  {'entities': [(49, 55, 'R_T')]}),\n",
       " ('kaplan-meier curve will be used to estimate the time-to-event distribution .',\n",
       "  {'entities': [(0, 18, 'R_F'), (35, 43, 'R_T'), (62, 74, 'R_T')]}),\n",
       " ('the 50th percentile of kaplan -meier estimate will be used to estimate the median duration of each endpoint .',\n",
       "  {'entities': [(37, 45, 'R_T'), (75, 81, 'R_T')]}),\n",
       " ('a 2-sided 95 % ci based on the brookmeyer-crowley method will be provided for this estimate .',\n",
       "  {'entities': [(10, 17, 'R_T'), (83, 91, 'R_T')]}),\n",
       " ('in addition , the event-free rate and 95 % ci at 12 month , 24 month , and 36 month for each treatment arm will be presented.the stratified hazard ratio ( talazoparib in combination with enzalutamide/control ) and the associated 95 % ci will be estimated using a cox proportional hazard model .',\n",
       "  {'entities': [(38, 45, 'R_T'), (147, 152, 'R_T')]}),\n",
       " ('both one-sided and two-sided p-values will be providedin summary table .',\n",
       "  {'entities': [(57, 70, 'R_T')]}),\n",
       " ('frequency ( number and percentage ) of patient with each event type ( progression [ including type of progression –i.e .',\n",
       "  {'entities': [(12, 33, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('reason for censoring will be summarized according to the category intable 6 .',\n",
       "  {'entities': [(29, 39, 'R_T')]}),\n",
       " ('if a patient meet multiple definition for censoringat the same visit , the list will be used to define the hierarchy .',\n",
       "  {'entities': [(75, 79, 'R_L')]}),\n",
       " ('table 6 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('3 event immediately after missing at least two event after missing assessment consecutive assessment 4 no event and withdrawal of consent date ≥ withdrawal of consent randomization dateor end of study ( eos ) = patient refused further follow-up 5 no event and lost to follow-up in any disposition page lost to follow-up 6 no event and eos present or disposition page for no adequate postbaselinetumor any epoch after screening say patient will not assessment continue into any subsequent phase of the study and no adequate postbaselinetumorassessment 7 no event and none of the condition in the prior ongoing without an event hierarchy are met median follow-up time will be estimated according to the kaplan-meier estimate of potential follow-up by the reverse kaplan-meier method .',\n",
       "  {'entities': [(644, 650, 'R_T'), (674, 682, 'R_T'), (167, 180, 'R_T')]}),\n",
       " ('an overview forest plot of rpfs based on bicr assessment bythe following subgroup will be presented .',\n",
       "  {'entities': [(12, 23, 'R_F')]}),\n",
       " ('a similar forest plot based on investigator assessment will also be provided .',\n",
       "  {'entities': [(10, 21, 'R_F')]}),\n",
       " ('\\uf0b7 age ( < 70/≥70 ) \\uf0b7 geographic region ( north america , european union [ eu ] /great britain [ gbr ] , asia , rest of world [ row ] ) \\uf0b7 easterncooperative oncologygroup ( ecog ) performance status at baseline ( 0 , 1 ) \\uf0b7 total gleason score at diagnosis ( < 8/≥8 ) \\uf0b7 type of progression at study entry ( psa only , radiographic progression with or without psa progression ) \\uf0b7 baseline psa ( < vs. ≥ overall median ) \\uf0b7 site of metastasis at study entry ( bone only , soft tissue only , both bone and soft tissue , none ) \\uf0b7 ddr status by iwrs ( ddr-deficient , non-deficient/unknown ) \\uf0b7 prior taxane or nht by iwrs ( yes/no ) 6.2.1.1 .',\n",
       "  {'entities': [(408, 414, 'R_T')]}),\n",
       " ('some of these sensitivity analysis will be presented in the csr , while the remaining will be presented in other summary document , for example , summary of clinical efficacy and summary of clinical safety .',\n",
       "  {'entities': [(113, 120, 'R_T')]}),\n",
       " ('rpfs will be calculated a the time interval from the date of randomization to the date of radiographic progression , death , discontinuation of study treatment ( both treatment component ) , start of a new anti-cancer therapy , or a symptomatic skeletal event , whichever occurs first .',\n",
       "  {'entities': [(61, 74, 'R_T'), (13, 23, 'R_T')]}),\n",
       " ('in addition , to ass the impact ofcovid-19 , the following sensitivity analysis of rpfs may be performed if covid-19 related death is reported in at least 10patients in the study : \\uf0b7 radiographic pfs based on bicr assessment and censoring \\uf0b7 death due to covid-19 .',\n",
       "  {'entities': [(134, 142, 'R_T')]}),\n",
       " ('bicr v investigator assessment : a separate summary of the bicr assessment versus investigator assessment will be provided for the all-comers population and for the ddr-deficient population .',\n",
       "  {'entities': [(44, 51, 'R_T')]}),\n",
       " ('the following category will be summarized by treatment arm for each population : \\uf0b7 agreement on time and occurrence of rpfs event ( within 28 day ) ( a1 ) , \\uf0b7 agreement on rpfs event but investigator event occurred later ( by > 28days ) ( a2 ) , \\uf0b7 agreement on rpfs event but investigator event occurred earlier ( by > 28days ) ( a3 ) , \\uf0b7 investigator assessment of rpfs event , patient censored in the bicr analysis ( b ) , \\uf0b7 patient censored in the investigator assessment analysis of rpfs , bicr assessment of rpfs event ( c ) , and \\uf0b7 agreement on non-occurrence of rpfs event ( d ) .',\n",
       "  {'entities': [(31, 41, 'R_T')]}),\n",
       " ('total event discrepancy rate ( b+c ) /n , early discrepancy rate ( a3+b ) / ( a+b ) , late discrepancy rate ( a2+c ) / ( a2+a3+b+c ) ; and overall discrepancy rate ( a2+a3+b+c ) /n will be calculated where a=a1+a2+a3.6.2.2 .',\n",
       "  {'entities': [(9, 10, 'R_T'), (189, 199, 'R_T')]}),\n",
       " ('overall survival o is defined a the time from randomization to the date of death due to any cause .',\n",
       "  {'entities': [(46, 59, 'R_T')]}),\n",
       " ('o ( month ) = [ date of deathor censoring –randomization date +1 ] /30.4375 .',\n",
       "  {'entities': [(43, 56, 'R_T')]}),\n",
       " ('aone-sided stratifiedlog-rank test will be performed on o in the all-comers population if the null hypothesis of rpfs in the all-comers population is rejected .',\n",
       "  {'entities': [(94, 109, 'R_T')]}),\n",
       " ('similarly , aone-sided stratified log-rank test of o will be performed in the ddr-deficient population if the null hypothesis of rpfs in the ddr-deficient population is rejected .',\n",
       "  {'entities': [(110, 125, 'R_T')]}),\n",
       " ('the stratified hazard ratio ( talazoparib in combination with enzalutamide/control ) and the associated 95 % ci will be estimated using a cox proportional hazard model .',\n",
       "  {'entities': [(104, 111, 'R_T'), (22, 27, 'R_T'), (97, 99, 'R_T')]}),\n",
       " ('both one-sided and two-sided p-values will be provided in summary table .',\n",
       "  {'entities': [(58, 71, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with a summary of associated statistic including the median o with two-sided 95 % ci .',\n",
       "  {'entities': [(64, 71, 'R_T'),\n",
       "    (110, 116, 'R_T'),\n",
       "    (134, 141, 'R_T'),\n",
       "    (79, 81, 'R_T'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (86, 95, 'R_T')]}),\n",
       " ('in addition , the survival rate and 95 % ci at 12months , 24months , 36months , and 48 month for each treatment arm will be presented a well .',\n",
       "  {'entities': [(36, 43, 'R_T')]}),\n",
       " ('reason for censoring will be summarized according to the category intable 7 .',\n",
       "  {'entities': [(29, 39, 'R_T')]}),\n",
       " ('ifa patient meet multiple definition for censoring , the list will be used to define the hierarchy .',\n",
       "  {'entities': [(57, 61, 'R_L')]}),\n",
       " ('table 7 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('censoring reason and hierarchy for o hierarchy condition censoring reason 1 no event and withdrawal of consent date ≥ withdrawal of consent randomization dateor eos= subject refused further follow-up 2 no event and lost to follow-up in any disposition page lost to follow-up 3 no event and none of the condition in the prior alive hierarchy are met frequency ( number and percentage ) of patient with anevent and censoring reason will be presented by treatment arm a follows : \\uf0b7 death o death due to covid-19 \\uf0b7 withdrawal of consent \\uf0b7 lost to follow-up\\uf0b7 ongoing and no death .',\n",
       "  {'entities': [(361, 382, 'R_T'), (349, 358, 'R_T'), (140, 153, 'R_T')]}),\n",
       " ('to ass the impact of covid-19 , the following sensitivity analysis of o may be performed by applying the additional censoring rule if covid-19 related death is reported in at least 10patietsin the study : \\uf0b7 censoringdeaths due to covid-19 .',\n",
       "  {'entities': [(160, 168, 'R_T')]}),\n",
       " ('table 8 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('incorporation of bone progression into best overall response overall soft example soft tissue tissue number timepoint response bone assessment response considering bone progression ( derived ) 1 week9 cr progression pd criterion met ( pd ) week 17 cr progression pd criterion confirmed 2 week 9 cr progression cr criterion met ( non-pd ) week 17 cr progression cr criterion not confirmed 3 week 9 sd non pd sd week 17 pr progression pdtable 8 .',\n",
       "  {'entities': [(397, 399, 'R_T')]}),\n",
       " ('incorporation of bone progression into best overall response overall soft example soft tissue tissue number timepoint response bone assessment response considering bone progression ( derived ) week 25 pr progression pd criterion confirmed best overall response willbe assessed on patient with measurable disease based on reported overall response at different evaluation timepoints from the date of randomization until documented disease progression ( in soft tissue per recist 1.1 or in bone per pcwg3 guideline ) or start of new antineoplastictherapyor curative radiotherapy where the treatment intent is specified a ‘ primary treatment ’ or surgery where the treatment intent is specified a ‘ curative in intent ’ andthe surgery outcome is either ‘ resected ’ or ‘ partially resected ’ , according to the following rule : \\uf0b7 cr = at least two determination of cr at least 4 week apart and documented before progression and start of new antineoplastictherapy \\uf0b7 pr = at least two determination of pr or better ( and not qualifying for a cr ) at least 4 week apart and before progression and start of new antineoplastic \\uf0b7 sd ( for patient with at least one measurable lesion at baseline ) = at least one sd assessment ( or better and not qualifying for cr or pr ) ≥ 8weeks after date of randomizationand before progression and the start of new antineoplastictherapy \\uf0b7 pd = progression ≤ 16weeks after date of randomizationand not qualifying for cr , pr or sd \\uf0b7 not evaluable ( ne ) = all other case .',\n",
       "  {'entities': [(321, 329, 'R_T'), (399, 412, 'R_T'), (1121, 1123, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('patient with best overall responseof ne will be summarized by reason for having ne status.\\uf0b7 no adequate baseline assessment \\uf0b7 early death ( defined a death prior to 8 week after date or randomization ) \\uf0b7 no postbaseline assessment due to covid-19 , i.e .',\n",
       "  {'entities': [(48, 58, 'R_T'), (186, 199, 'R_T')]}),\n",
       " ('participant miss tumor assessment visit due to covid-19 pandemic \\uf0b7 no postbaselineassessments due to other reason \\uf0b7 all postbaselineassessments have overall response ne \\uf0b7 new antineoplastictherapy started before first postbaselineassessment \\uf0b7 sd of insufficient duration ( < 8 week after date of randomization ) \\uf0b7 pd too late ( > 16weeks after date of randomization ) special and rare case where the best overall responseis ne due to both early sd and late pd will be classified a ‘ sd of insufficient duration ’ .',\n",
       "  {'entities': [(296, 309, 'R_T'), (243, 245, 'R_T')]}),\n",
       " ('orr by treatment arm will be calculated along with the two-sided 95 % ciusing a cochran– mantel–haenszel test .',\n",
       "  {'entities': [(29, 39, 'R_T')]}),\n",
       " ('kaplan-meier estimate ( product-limit estimate ) will be presented by treatment arm together with a summary of associated statistic including the median dr time with two-sided 95 % ci .',\n",
       "  {'entities': [(176, 183, 'R_T'),\n",
       "    (122, 131, 'R_T'),\n",
       "    (115, 117, 'R_T'),\n",
       "    (100, 107, 'R_T'),\n",
       "    (146, 152, 'R_T'),\n",
       "    (13, 21, 'R_T')]}),\n",
       " ('the ci for the median will be calculated according to brookmeyer and crowley .',\n",
       "  {'entities': [(4, 6, 'R_T'), (30, 40, 'R_T'), (15, 21, 'R_T')]}),\n",
       " ('inferential statistic ( e.g .', {'entities': [(12, 21, 'R_T')]}),\n",
       " ('hazard ratio and p-value ) will not be provided for duration of response given that the analysis is performed on the responder only , not the itt population .',\n",
       "  {'entities': [(17, 24, 'R_T'), (7, 12, 'R_T')]}),\n",
       " ('duration of soft tissue response will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(41, 49, 'R_T')]}),\n",
       " ('the percentage of patient in the itt population with maximum psa decline of at least 50 % will be calculated along with the two-sided 95 % ci .',\n",
       "  {'entities': [(134, 141, 'R_T'),\n",
       "    (4, 14, 'R_T'),\n",
       "    (53, 60, 'R_T'),\n",
       "    (98, 108, 'R_T')]}),\n",
       " ('the difference in response rate between treatment arm along with both one-sided and two-sided p-values for the difference in will be providedusing a cochran–mantel–haenszel test in summary table .',\n",
       "  {'entities': [(181, 194, 'R_T')]}),\n",
       " ('psa ( ng/ml ) will also be summarized descriptively by visit .',\n",
       "  {'entities': [(27, 37, 'R_T')]}),\n",
       " ('psa response will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(21, 29, 'R_T')]}),\n",
       " ('time to psa progression psa progression is defined a the timefrom the date of randomization to the date of the first psa value demonstrating progression , which is subsequently confirmed .',\n",
       "  {'entities': [(78, 91, 'R_T')]}),\n",
       " ('patient without any post baseline assessment will be censored at randomization .',\n",
       "  {'entities': [(65, 78, 'R_T')]}),\n",
       " ('psa progression ( month ) = [ date of psa progression or censoring –randomization date +1 ] /30.4375 .',\n",
       "  {'entities': [(68, 81, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('frequency ( number and percentage ) of patient with anevent orcensoring will be presented by treatment arm.time to psa progression will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(12, 33, 'R_T'), (139, 147, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('time to initiation of cytotoxic chemotherapy time to initiation of cytotoxic chemotherapy is defined a the time from randomization to the first use of cytotoxic chemotherapy .',\n",
       "  {'entities': [(117, 130, 'R_T')]}),\n",
       " ('cytotoxic chemotherapy will be identified based on a clinical review of all follow-up cancer therapy reported on the follow-up therapy crf page .',\n",
       "  {'entities': [(101, 109, 'R_T')]}),\n",
       " ('result will be reported in month ( [ date of event or censoring –randomization ] ) /30.4375 .',\n",
       "  {'entities': [(65, 78, 'R_T'), (15, 23, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('frequency ( number and percentage ) of patient with anevent orcensoring will be presented by treatment arm .',\n",
       "  {'entities': [(12, 33, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('time to initiation of antineoplastic therapy time to initiation of antineoplastic therapy is defined a the time from randomization to the first use of antineoplastic therapy .',\n",
       "  {'entities': [(117, 130, 'R_T')]}),\n",
       " ('they will be identified based on a clinical review of all follow-up cancer therapy reported on the follow-up therapy crf page .',\n",
       "  {'entities': [(83, 91, 'R_T')]}),\n",
       " ('result will be reported in month ( [ date of event or censoring –randomization ] ) /30.4375 .',\n",
       "  {'entities': [(65, 78, 'R_T'), (15, 23, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('the result will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(19, 27, 'R_T')]}),\n",
       " ('time to first symptomatic skeletal event time to the first symptomatic skeletal event is defined a the time from randomization to the date of the first symptomatic fracture , surgery to the bone , radiotherapy to the bone , or spinal cord compression a reported on the skeletal related event crf page .',\n",
       "  {'entities': [(113, 126, 'R_T'), (253, 261, 'R_T')]}),\n",
       " ('analysis will be in month ( [ date of event or censoring –randomization ] ) /30.4375.time to the first symptomatic skeletal event will be analyzedusing a one-sided stratified log- rank test .',\n",
       "  {'entities': [(58, 71, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('the result will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(19, 27, 'R_T')]}),\n",
       " ('pfs2 based on investigator assessment pfs2 is defined a the time from randomization to investigator documented disease progression ( psa progression , progression on imaging , or clinical progression ) on the first subsequent antineoplastic therapy for prostate cancer , or death from any cause , whichever occurs first .',\n",
       "  {'entities': [(70, 83, 'R_T')]}),\n",
       " ('pfs2 ( month ) = [ date of event/censoring –date of randomization +1 ] /30.4375 a patient will be considered to have an event if : \\uf0b7 date of documented progression on the first subsequent antineoplastic therapy is provided on follow-up cancer therapy crf page ; or \\uf0b7 the patient dy .',\n",
       "  {'entities': [(52, 65, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('both one-sided and two-sided p-values will be provided in summary table .',\n",
       "  {'entities': [(58, 71, 'R_T')]}),\n",
       " ('the frequency ( number and percentage ) of patient with an event and censoring reason will be presented by treatment arm .',\n",
       "  {'entities': [(16, 37, 'R_T'), (4, 13, 'R_T')]}),\n",
       " ('table 9 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('b if there is no adequate postbaseline assessment , then the censoring date is the date of randomization .',\n",
       "  {'entities': [(91, 104, 'R_T')]}),\n",
       " ('c ntx1 is the first new anticancer regimen the pfs2results will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(67, 75, 'R_T')]}),\n",
       " ('time to opiate use for prostate cancer pain time to opiate use for prostate cancer pain is defined a the time from date of randomization to the date of the first or new opiate medication for prostate cancer painstarted after randomization and will be based on the start date of medication reported on the concomitant medication page of the crf reported with a category of ‘ opioids ’ .',\n",
       "  {'entities': [(289, 297, 'R_T'), (123, 136, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .',\n",
       "  {'entities': [(66, 72, 'R_T'), (77, 84, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('the result will be reported forboth the all-comers population and the ddr-deficient population .',\n",
       "  {'entities': [(19, 27, 'R_T')]}),\n",
       " ('time to event endpoint time to deterioration in patient-reported pain symptom per bpi-sf patient-reported pain symptom ( per the pain log – bpi-sf question 3 ) will be completed for 7 consecutive day beforeeachstudy visit .',\n",
       "  {'entities': [(56, 64, 'R_T')]}),\n",
       " ('pain score average during each visit period will be calculated and will be used for the analysis of time to deterioration in patient-reported pain symptom .',\n",
       "  {'entities': [(133, 141, 'R_T'), (11, 18, 'R_T'), (52, 62, 'R_T')]}),\n",
       " ('time to deterioration in patient-reported pain symptom per bpi-sf is assessed using the average pain score from the bpi-sf question 3 : “ please rate your pain by marking the box beside the number that best describes your pain at it worst in the last 24 hours. ” time to this event is defined a the time from randomization to onset of pain progression , where pain progression is defined a a ≥2 point increase from baseline in the question 3 scorefor two consecutive visit period at least 4 week apart without a decrease in who analgesic usage score .',\n",
       "  {'entities': [(88, 95, 'R_T'), (309, 322, 'R_T'), (33, 41, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented together with a summary of associated statisticsfrequency ( number and percentage ) of patient with an event or censoring will be presented .',\n",
       "  {'entities': [(56, 63, 'R_T'), (100, 121, 'R_T'), (13, 21, 'R_T')]}),\n",
       " ('time to definitive deterioration in patient-reported global health status/qol per eortc qlq-c30 time to definitive deterioration in patient-reported global health status/qol per eortc qlq-c30is defined a the time fromrandomization to the firstdefinitive deterioration defined a a ≥ 10-point decrease from baseline and no subsequent observation of a < 10-point decrease from baseline .',\n",
       "  {'entities': [(44, 52, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented together with a summary of associated statistic including the median and quartile with two-sided 95 % ci .',\n",
       "  {'entities': [(102, 108, 'R_T'),\n",
       "    (71, 73, 'R_T'),\n",
       "    (56, 63, 'R_T'),\n",
       "    (137, 144, 'R_T'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (78, 87, 'R_T')]}),\n",
       " ('frequency ( number and percentage ) of patient with an event or censoring will be presented .',\n",
       "  {'entities': [(12, 33, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('time to definitive deterioration in patient-reported disease-specific urinary symptom per eortc qlq-pr25 time to definitive deterioration in patient-reported disease-specific urinary symptom per eortc qlq-pr25 is defined a the time fromrandomization to the firstdefinitive deterioration defined a a ≥ 10-point increase from baseline and no subsequent observation of a < 10point increase from baseline .',\n",
       "  {'entities': [(44, 52, 'R_T')]}),\n",
       " ('kaplan-meier estimate will be presented together with a summary of associated statistic including the median and quartile with two-sided 95 % ci .',\n",
       "  {'entities': [(102, 108, 'R_T'),\n",
       "    (71, 73, 'R_T'),\n",
       "    (56, 63, 'R_T'),\n",
       "    (137, 144, 'R_T'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (78, 87, 'R_T')]}),\n",
       " ('frequency ( number and percentage ) of patient with an event or censoring will be presented .',\n",
       "  {'entities': [(12, 33, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('descriptivesummaries and change from baseline bpi-sf descriptive summary for bpi-sfby visit will be provided .',\n",
       "  {'entities': [(65, 72, 'R_T')]}),\n",
       " ('these include : \\uf0b7 for each visit period ( collectively for study visit and the 7 consecutive day prior to each study visit ) , number and percentage of patient who completed all the bpsi-sf question 3 out of a total of 8 ) , ≥4 of the bpi-sf question 3 , and those who did not complete any bpi-sf question 3 will be summarized \\uf0b7 descriptive summary of the average score at each visit period for bpi-sf question3 o each pain intensity is a whole number ( 0 through 10 ) and will be summarized a a continuous variable o missing value ( < 4 of8 possible assessment per visit period ) are not included in the summariesdescriptive statistic for change from baseline in patient-reported pain symptom per bpi- sf ( question 3 ) will be summarized for each visit period .',\n",
       "  {'entities': [(127, 148, 'R_T'),\n",
       "    (626, 635, 'R_T'),\n",
       "    (341, 348, 'R_T'),\n",
       "    (496, 515, 'R_T'),\n",
       "    (356, 363, 'R_T'),\n",
       "    (316, 326, 'R_T'),\n",
       "    (672, 680, 'R_T')]}),\n",
       " ('a graphical display of mean over time a well a mean change from baseline over time will also be provided .',\n",
       "  {'entities': [(23, 27, 'R_T')]}),\n",
       " ('a longitudinal mixed effect model will also be used to summarize the change from baseline pain symptom score ( bpi-sf question 3 ) across all visit period .',\n",
       "  {'entities': [(55, 64, 'R_T')]}),\n",
       " ('eq-5d-5l health index analysis of the eq-5d health index will consist of descriptive statistic on mean and change from baseline , overall change from baselineusing a longitudinal mixed effect model , and graphical display of mean and change from baseline over time .',\n",
       "  {'entities': [(85, 94, 'R_T'), (98, 102, 'R_T')]}),\n",
       " ('in addition , there will be a health status profile analysis consisting of adisplay of the number and percentage of patient in each of the 5response level for each ofthe 5 dimension at each visit .',\n",
       "  {'entities': [(91, 112, 'R_T')]}),\n",
       " ('eq-5d general health status ( eq-5d va ) analysis of eq-5d va will consist of descriptive statistic on mean and change from baseline , overall change from baselineusing a longitudinal mixed effect model , and graphical display of mean and change from baseline over time .',\n",
       "  {'entities': [(103, 107, 'R_T'), (90, 99, 'R_T')]}),\n",
       " ('qlq-c30 analysis of the qlq-c30will consist of descriptive statistic for each scale on mean and change from baseline , overall change from baselineusing a longitudinal mixed effect model , time to definitive deterioration , and graphical display of mean and change from baseline over time .',\n",
       "  {'entities': [(87, 91, 'R_T'), (59, 68, 'R_T')]}),\n",
       " ('qlq-pr25 analysis of the qlq-pr25 will consist of descriptive statistic for each scale on mean andchanges from baseline , overall change from baselineusing a longitudinal mixed effectsmodel , time to definitive deterioration , and graphical display of mean and change from baseline over time .',\n",
       "  {'entities': [(62, 71, 'R_T'), (90, 94, 'R_T')]}),\n",
       " ('separate summary of dose-normalized c by scheduled visit trough for patient in part 2 may also be generated.6.2.5 .',\n",
       "  {'entities': [(9, 16, 'R_T')]}),\n",
       " ('for ctc count , a summary of the mean ( standard deviation ) , median , and range of baseline and postbaselinevalues will be provided for patient in thectc evaluable set .',\n",
       "  {'entities': [(63, 69, 'R_T'),\n",
       "    (76, 81, 'R_T'),\n",
       "    (40, 58, 'R_T'),\n",
       "    (18, 25, 'R_T'),\n",
       "    (33, 37, 'R_T')]}),\n",
       " ('in addition , the number and percentage of patient with ctc count ≥ 5 vs. < 5 and ctc count > 0 vs. =0 per 7.5 ml will be presented a well .',\n",
       "  {'entities': [(18, 39, 'R_T')]}),\n",
       " ('the proportion of patient with a conversion will be calculated along with the two-sided 95 % ciusing the clopper-pearson method .',\n",
       "  {'entities': [(52, 62, 'R_T')]}),\n",
       " ('the proportion of patient with such a conversionwill be calculated along with the two-sided 95 % ciusing the clopper-pearson method .',\n",
       "  {'entities': [(56, 66, 'R_T')]}),\n",
       " ('the proportion of patient with such a conversion will be calculated along with the two-sided 95 % ciusing the clopper-pearson method .',\n",
       "  {'entities': [(57, 67, 'R_T')]}),\n",
       " ('subgroup analysis subgroup analysis will be performed if there is a sufficient sample size .',\n",
       "  {'entities': [(79, 90, 'R_T')]}),\n",
       " ('some of the subgroup analysis will be presented in the csr , while the remaining will be presented in other summary document , for example , summary of clinical efficacy and summary of clinical safety .',\n",
       "  {'entities': [(108, 115, 'R_T')]}),\n",
       " ('besides the subgroup analysis presented in the overview forest plot described in section6.2.1 , the following additional subgroup analysis will be performed for rpfs by bicr where the subgroup are subset of the all-comers population : \\uf0b7 ddr mutational status derived using prospective/retrospective data ( subgroup definition 2-6in section 5.2.7 ) .',\n",
       "  {'entities': [(56, 67, 'R_F')]}),\n",
       " ('\\uf0b7 renal impairment ( moderate , mild , normal ) \\uf0b7 race ( asian , white , african american , other ) \\uf0b7 prior nht ( yes , no ) \\uf0b7 prior docetaxel ( yes , no ) \\uf0b7 baseline bone protecting agent ( yes , no ) \\uf0b7 baseline ldh value ( < vs. ≥ median ) \\uf0b7 baseline hemoglobin value ( < vs. ≥ median ) \\uf0b7 baseline alp value ( < vs. ≥ median ) \\uf0b7 baseline ctc count ( < 5 , ≥ 5 ) \\uf0b7 baseline ctc count ( 0 , > 0 ) similarsubgroup analysis will be performed for cohort 2 .',\n",
       "  {'entities': [(233, 239, 'R_T')]}),\n",
       " ('subgroup analysis of other efficacy parameter and subgroup analysis for part 1 data are not planned .',\n",
       "  {'entities': [(36, 45, 'R_T')]}),\n",
       " ('≥ 70 ) , \\uf0b7 asian vs. non-asian.normal , mild , and moderate renal impairment are defined based on baseline egfr of ≥90 ml/min/1.73m2 , 60-89 ml/min/1.73m2 , and30-59ml/min/1.73m2 respectively , where egfr willbe captured on the crfs .',\n",
       "  {'entities': [(122, 125, 'R_T')]}),\n",
       " ('additionally adverse event listing will consider the dose at the time of the start of the event .',\n",
       "  {'entities': [(27, 34, 'R_L')]}),\n",
       " ('baseline and other summary unless otherwise specified , the following summary will be provided separately for the safety analysis set of part 1 and for the itt all-comers and ddr-deficient population in part 2 .',\n",
       "  {'entities': [(19, 26, 'R_T')]}),\n",
       " ('for part 1 , select data may be listed instead of summarized .',\n",
       "  {'entities': [(32, 38, 'R_L'), (50, 60, 'R_T')]}),\n",
       " ('baseline summary thefollowingdemographic andbaselinedisease characteristicswill besummarized : \\uf0b7 age ( continuous and by group : < 65 ; 65- < 75 ; > =75 ) \\uf0b7 race \\uf0b7 asian vs. non-asian \\uf0b7 weight \\uf0b7 body mass index ( bmi ) \\uf0b7 geographic region ( northamerica , europe , asia , rest of world ) \\uf0b7 renal impairment at baseline ( normal , mild , moderate ) , o normal , mild , and moderate are defined based on baseline baseline egfr of ≥90 ml/min/1.73m2 , 60-89 ml/min/1.73m2 , and 30-59ml/min/1.73m2 , respectively , \\uf0b7 histopathological classification \\uf0b7 baseline serum psa ( ng/ml ) \\uf0b7 baseline useof aboneprotecting agent ( yes , no ) \\uf0b7 gleason score ( low [ 2-4 ] , medium [ 5-7 ] , high [ 8-10 ] ) \\uf0b7 gleason score ( < =6 , 3+4=7 , 4+3=7 , 8 , 9-10 , not reported ) \\uf0b7 ecogperformance status \\uf0b7 tnm stageat diagnosis \\uf0b7 tnm stage at study entry \\uf0b7 disease localization at screening : o bone only o soft tissue only o both bone and soft tissue o none\\uf0b7 distribution of disease at screening : o bone ( includes bone with soft tissue component ) o lymph node o visceral disease ( lung or liver ) o visceral disease ( lung ) o visceral disease ( liver ) o other soft tissue \\uf0b7 number of bone metastasis at screening : n ( % ) o 0 o 1-4 o 5-9 o 10-20 o > 20 \\uf0b7 type of progression at study entry : o psa progression only o bone progression only o soft tissue progression only o psa+ bone or soft tissue o bone+ psa or soft tissue o psa+bone+soft tissue \\uf0b7 baselinepain score by bp-sf ( 0-1 ; 2-3 ; > 3 ) , \\uf0b7 baseline ctc count o continuous summary o categorical summary ( ≥ 5 ctc per 7.5 ml of blood , < 5 ctc per 7.5 ml of blood ) o categorical summary ( > 0 ctc per 7.5 ml of blood , 0 ctc per 7.5 ml of blood ) \\uf0b7 time from primary diagnosis to randomization in month ( date of randomization – date of diagnosis ) /30.4375 \\uf0b7 derived ddr mutational status ( positive , negative , unknown ) with specific mutation prior to randomization \\uf0b7 ddr mutational status ( positive , negative , unknown ) with specific mutation based on blood sample only \\uf0b7 ddr mutational status ( positive , negative , unknown ) with specific mutationsbased on tumor tissue sample onlythe number of patient in the following category at the time of randomization will be summarized : \\uf0b7 prior nht ortaxane and ddr-deficient \\uf0b7 prior nht or taxane and non ddr-deficient/unknown \\uf0b7 no prior nht ortaxane and ddr-deficient \\uf0b7 no prior nht or taxane and non ddr-deficient/unknown a listing will be provided with the stratum ( defined above ) at the time of randomization a well a based on crf data with a flag to indicate case where there are difference between the derived data and the iwrs data at the time of randomization .',\n",
       "  {'entities': [(2014, 2020, 'R_T'),\n",
       "    (6, 7, 'R_T'),\n",
       "    (435, 438, 'R_T'),\n",
       "    (1728, 1741, 'R_T'),\n",
       "    (2428, 2435, 'R_L'),\n",
       "    (82, 92, 'R_T'),\n",
       "    (941, 953, 'R_T'),\n",
       "    (186, 192, 'R_T'),\n",
       "    (9, 16, 'R_T'),\n",
       "    (749, 757, 'R_T')]}),\n",
       " ('medical history medical history will be coded using the most current version of meddra and summarized by meddra ’ s soc and pt .',\n",
       "  {'entities': [(91, 101, 'R_T')]}),\n",
       " ('summary will be ordered by primary soc and pt in descending order of frequency by the experimental treatment arm .',\n",
       "  {'entities': [(0, 7, 'R_T'), (69, 78, 'R_T')]}),\n",
       " ('summary will be provided for all patient in the itt population .',\n",
       "  {'entities': [(0, 7, 'R_T')]}),\n",
       " ('the number and percentage of patient in each of the following anticancer therapy category will be tabulated : \\uf0b7 patient with at least one type of prior anticancer systemic treatment including androgen deprivation therapy ; \\uf0b7 patient with at least one prior anticancer surgery ; \\uf0b7 patient with at least one prior anticancer radiotherapywith “ primary treatment ” and “ salvage ” intent ; \\uf0b7 patient with any prior androgen deprivation therapy .',\n",
       "  {'entities': [(4, 25, 'R_T'), (98, 107, 'R_T')]}),\n",
       " ('prior anticancer drug therapy will be summarized a follows based on the number and percentage of patient : o number of prior anticancer therapy regimen ( including androgen deprivation therapy ) : none/ 1 / 2 / ≥3 .',\n",
       "  {'entities': [(72, 93, 'R_T'), (38, 48, 'R_T')]}),\n",
       " ('the prior anticancerdrugs will be coded in the who drug coding dictionary and will be summarized usingthe number and percentage of patient by preferred term .',\n",
       "  {'entities': [(86, 96, 'R_T'), (106, 127, 'R_T')]}),\n",
       " ('in case of equal frequency , alphabetical order will be used .',\n",
       "  {'entities': [(17, 26, 'R_T')]}),\n",
       " ('a summary of the number of patient with the followingprior cancersurgeries will be provided : \\uf0b7 prostatectomy , \\uf0b7 turp , \\uf0b7 prostate biopsy , \\uf0b7 bilateral orchiectomy , \\uf0b7 pelvic node dissection , \\uf0b7 ureteral stent , \\uf0b7 nephrostomy .',\n",
       "  {'entities': [(2, 9, 'R_T')]}),\n",
       " ('specific detail on all other surgery and radiotherapy ( primary treatment and salvage ) will be provided in data listing .',\n",
       "  {'entities': [(113, 120, 'R_L')]}),\n",
       " ('if multiple event lead to study treatment discontinuation and at least one wa considered related , discontinuation will be reported a related to study treatment .',\n",
       "  {'entities': [(123, 131, 'R_T')]}),\n",
       " ('the listing will present subject number identifier byinvestigational site , and a description of covid-19-related event including : \\uf0b7 all protocol deviation \\uf0b7 related aesif available \\uf0b7 death 6.4.5 .',\n",
       "  {'entities': [(4, 11, 'R_L')]}),\n",
       " ('protocol deviation important protocol deviation will be compiled prior to database release and will be summarized by category ( n ( % ) ) using the safety population for part 1 andthe itt population forpart 2.categories will be assigned by the study team .',\n",
       "  {'entities': [(103, 113, 'R_T'), (17, 18, 'R_T')]}),\n",
       " ('in addition , all protocol deviation related to covid-19 will be presented in a separate listing.6.4.6 .',\n",
       "  {'entities': [(80, 96, 'R_L')]}),\n",
       " ('study treatment exposure exposure summary will be presented using the safety analysis set for each part .',\n",
       "  {'entities': [(34, 41, 'R_T')]}),\n",
       " ('thestartingtalazoparib dosewill be 0.35mg/dayin combination withenzalutamide 160 mg/dayforpatients with moderaterenal impairment ( egfr 30-59ml/min/1.73m2 ) .',\n",
       "  {'entities': [(144, 147, 'R_T')]}),\n",
       " ('separate summary will be provided for talazoparib and enzalutamide and will include the following : \\uf0b7 treatment duration ( month ) : foreachpatient , treatmentdurationis definedas ( date of last dose–dateof first dose +1 ) / 30.4375 .',\n",
       "  {'entities': [(9, 16, 'R_T')]}),\n",
       " ('\\uf0b7 average dailydose ( mg/day ) : theaveragedailydoseis definedas the cumulative dosedividedbythe actual number of day on the treatment .',\n",
       "  {'entities': [(2, 9, 'R_T')]}),\n",
       " ('\\uf0b7 relative dose intensity ( % ) : relative dose intensity is defined a the ratio of the actual dose intensity to the planned dose intensity expressed in % .',\n",
       "  {'entities': [(75, 80, 'R_T')]}),\n",
       " ('a dose reduction is defined a a non-zero dose that is le than the prior dose.the number andpercentage of patient with at least one dose reductionas well a a breakdown of dose reduction ( 1 / 2 / 3 ) will be summarized by treatment arm .',\n",
       "  {'entities': [(207, 217, 'R_T')]}),\n",
       " ('reason for dose reduction will also be summarized .',\n",
       "  {'entities': [(39, 49, 'R_T')]}),\n",
       " ('percentage will be calculated based on the total number of patient in safety analysis set .',\n",
       "  {'entities': [(19, 29, 'R_T'), (0, 10, 'R_T')]}),\n",
       " ('the number and percentage of patient with dosing interruption and the corresponding reason will be summarized by treatment arm .',\n",
       "  {'entities': [(4, 25, 'R_T'), (99, 109, 'R_T')]}),\n",
       " ('percentage will be calculated based on the total number of patient in safety analysis set .',\n",
       "  {'entities': [(19, 29, 'R_T'), (0, 10, 'R_T')]}),\n",
       " ('time to first interruption ( week ) and time to first reduction ( week ) , measured from the date of first dose of study treatment , will be summarized for patient who had at least one interruption or reduction respectively .',\n",
       "  {'entities': [(141, 151, 'R_T')]}),\n",
       " ('a summary of duration ( day ) of dosinginterruptions due to any aes and for anemia only for each dosinginterruption will be provided , where ‘ n ’ is the number of dosing interruption .',\n",
       "  {'entities': [(2, 9, 'R_T'), (20, 21, 'R_T')]}),\n",
       " ('a summary of the total duration ( day ) of dosinginterruptions due to aes for each patient will also be provided .',\n",
       "  {'entities': [(2, 9, 'R_T')]}),\n",
       " ('concomitant medication concomitant medication refer to all medication thatstarted or were ongoing at the time of randomization , started after randomization and continued during the on-treatment period for up to 28 day after the last dose of all the study treatment a well a those started during the on-treatment period .',\n",
       "  {'entities': [(113, 126, 'R_T')]}),\n",
       " ('concomitant medication will be coded in the who drug coding dictionary and will be tabulated by anatomical therapeutic chemical ( atc ) classification level 2 and preferred term in descending order of frequencyfor the talazoparib in combination with enzalutamidearm .',\n",
       "  {'entities': [(83, 92, 'R_T')]}),\n",
       " ('in case of equal frequency regarding drug class ( respectively drug name ) , alphabetical order will be used .',\n",
       "  {'entities': [(17, 26, 'R_T')]}),\n",
       " ('non-drug treatment will be coded in meddra and will be summarized by meddra soc and pt in descending order of frequencyon the talazoparib in combination with enzalutamidearm .',\n",
       "  {'entities': [(55, 65, 'R_T')]}),\n",
       " ('concomitant medication and non-drug treatment will be summarized by treatment arm for the part 1 and part 2 safety population .',\n",
       "  {'entities': [(54, 64, 'R_T')]}),\n",
       " ('concomitant medication in will be listed for part 1 and part 2 .',\n",
       "  {'entities': [(34, 40, 'R_L')]}),\n",
       " ('the number and percentage of patient within each category ( medication therapy , radiation therapy , and surgery ) will be provided by treatment arm for thepart 2 itt population .',\n",
       "  {'entities': [(4, 25, 'R_T')]}),\n",
       " ('subsequent anticancertherapies and procedure will be listed for part 1 and part 2 .',\n",
       "  {'entities': [(53, 59, 'R_L')]}),\n",
       " ('medication will be coded using the who drug coding dictionary and will be tabulated by preferred term in descending order of frequency.6.5 .',\n",
       "  {'entities': [(74, 83, 'R_T'), (125, 134, 'R_T')]}),\n",
       " ('safety summary and analysis unless otherwise specified , summary of aes and other safety parameter will provided separately for part 1 and part 2 and will be based on the safety population .',\n",
       "  {'entities': [(7, 14, 'R_T'), (89, 98, 'R_T')]}),\n",
       " ('treatment assignment will still be blinded ) at the time of the final analysis of rpfs in the all- comer population , summary will initially be performed only for the all-comers population .',\n",
       "  {'entities': [(118, 125, 'R_T')]}),\n",
       " ('at the time of the final rpfs analysis in the ddr-deficient population safety data will be summarized for the combined population of all-comers and ddr-deficient patient in part 2 .',\n",
       "  {'entities': [(91, 101, 'R_T')]}),\n",
       " ('aes not considered treatment-emergent will be flagged in data listing .',\n",
       "  {'entities': [(62, 69, 'R_L')]}),\n",
       " ('for part 1 and part 2 separately , ahigh-level summary of adverse event will include the number and percent of patient with : \\uf0b7 any ae ; \\uf0b7 serious ae ; \\uf0b7 ctcae grade 3-4 aes ; \\uf0b7 grade 5 aes ; \\uf0b7 aes leading to dose reduction of talazoparib/placebo ; \\uf0b7 aes leading to dose reduction of enzalutamide ; \\uf0b7 aes leading to dose reduction of both talazoparib/placebo and enzalutamide ; \\uf0b7 aes leading to dosinginterruptions of talazoparib/placebo ; \\uf0b7 aes leading to dosinginterruptions of enzalutamide ; \\uf0b7 aes leading to dosing interruption of both talazoparib/placebo and enzalutamide ; \\uf0b7 aes leading to permanent discontinuationof talazoparib/placebo ; \\uf0b7 aes leading to permanent discontinuationof enzalutamide ; \\uf0b7 aes leading to permanent discontinuation of both talazoparib/placebo and enzalutamide .',\n",
       "  {'entities': [(47, 54, 'R_T')]}),\n",
       " ('seriousness , toxicity grade , action taken ( interruption , reduction , and withdraw ) are a reported by the investigator on the adverse event crf .',\n",
       "  {'entities': [(94, 105, 'R_T')]}),\n",
       " ('summary soc and pt by treatment arm in decreasing frequency will be provided for : \\uf0b7 treatment-emergent aes ( all causality ) ; \\uf0b7 treatment-emergent aes by maximum ctcaegrade ( all causality ) ; \\uf0b7 treatment-emergent covid-19 related aes ( all causality ) ; \\uf0b7 treatment-emergent aes ( treatment related ) ; \\uf0b7 treatmen -emergent aes by maximum ctcae grade ( treatment related ) ; \\uf0b7 serious treatment-emergent aes ( all causality ) ; \\uf0b7 serious treatment-emergent aes ( treatment related ) ; an aewill be considered treatment related if the investigator considered the event related to one or both of study drug given in combination .',\n",
       "  {'entities': [(156, 163, 'R_T'), (50, 59, 'R_T'), (0, 7, 'R_T')]}),\n",
       " ('the following summary of aes will be provided by decreasing frequency of pt ( summary will not include soc ) in the talazoparib plus enzalutamidearm for part 2 only : \\uf0b7 treatment-emergent aes ( all causality ) in either treatment arm ; \\uf0b7 treatment-emergent aes ( all causality ) by preferred term and maximum ctcae grade ; \\uf0b7 treatment-emergent aes leading to dosing interruption of talazoparib ( all causality ) ; \\uf0b7 treatment-emergent aes leading to dosing interruption of enzalutamide ( all causality ) ; \\uf0b7 treatment-emergent aes leading to dosing interruption of bothtalazoparib and enzalutamide ( all causality ) ; \\uf0b7 treatment emergent aes leading to dose reduction of talazoparib ( all causality ) ; \\uf0b7 treatment emergent aesleading to dose reduction of enzalutamide ( all causality ) ; \\uf0b7 treatment emergent aesleading to dose reduction of both talazoparib and enzalutamide ( all causality ) ; \\uf0b7 treatment emergent aes leading to permanent withdraw of talazoparib ( all causality ) ; \\uf0b7 treatment emergent aes leading to permanent withdraw of enzalutamide ( all causality ) ; \\uf0b7 treatment emergent aes leading to permanent withdraw of both talazopariband enzalutamide ( all causality ) ; \\uf0b7 treatment emergent aes between ddr-deficient patient and non-deficient patient ( all causality ) ; \\uf0b7 treamtment emergent ae between normal/mild vesusmoderate renal impareiment ( all causality ) \\uf0b7 serious treatment emergent aes ( treatment related ) .',\n",
       "  {'entities': [(14, 21, 'R_T'), (301, 308, 'R_T'), (60, 69, 'R_T')]}),\n",
       " ('if a patient ha event with missing and non-missing toxicity grade , the maximum non- missing grade will be displayed .',\n",
       "  {'entities': [(72, 79, 'R_T')]}),\n",
       " ('missing grade will only be displayed in the event that only one aehas been reported for a patient and the grade is missing .',\n",
       "  {'entities': [(75, 87, 'R_T')]}),\n",
       " ('summary of time to first grade 3 or 4 event and time to first sae will also be providedfor the safety population in part 2 .',\n",
       "  {'entities': [(0, 7, 'R_T')]}),\n",
       " ('adverse event of special interest see section 3.4.1for a list of aes of special interest .',\n",
       "  {'entities': [(57, 61, 'R_L')]}),\n",
       " ('for talazoparib aesis , separate summary for each aesi will be provided by maximum toxicity and will include an ‘ any event ’ row along with a row for each contributing pt in descending order of frequency .',\n",
       "  {'entities': [(195, 204, 'R_T'), (75, 82, 'R_T'), (33, 40, 'R_T')]}),\n",
       " ('given the observed incidence of hematologic toxicity associated with the use of talazoparib , a summary of hematologic aes will be provided toshow the incidence of the following cluster term : \\uf0b7 anemia : anaemia , decreased hemoglobin , decreased hematocrit , red blood cell count decreased \\uf0b7 neutropenia : neutropenia and decreased neutrophil count \\uf0b7 thrombocytopenia : thrombocytopenia and platelet count decreased \\uf0b7 leukopenia : leukopenia or white blood cell count decreased \\uf0b7 lymphopenia : lymphopenia or lymphocyte count decreased aesis for enzalutamide will be summazried by medical event only , not by individual contributing pt if applicable .. 6.5.3 .',\n",
       "  {'entities': [(96, 103, 'R_T')]}),\n",
       " ('death the frequency ( number and percentage ) of patient in the safety populationwho died anddeath , will be tabulated based on information from the ‘ notice of death ’ and ‘ survival follow-up ’ crfs .',\n",
       "  {'entities': [(109, 118, 'R_T'), (10, 19, 'R_T'), (22, 43, 'R_T')]}),\n",
       " ('date and cause of death will be provided in individual patient data listing with selected dosing information ( study treatment received , date of first / last administration , dose , etc . ) .',\n",
       "  {'entities': [(68, 75, 'R_L')]}),\n",
       " ('in addition , if there are ≥ 10deaths due to covid-19 , a separate death summary will be createdfor covid-19 related death .',\n",
       "  {'entities': [(73, 80, 'R_T')]}),\n",
       " ('quantitative data will be summarized using descriptive statistic ( mean , standard deviation , median , quartile , minimum , and maximum ) of actual value and change from baseline for each visit over time ( i.e .',\n",
       "  {'entities': [(67, 71, 'R_T'),\n",
       "    (95, 101, 'R_T'),\n",
       "    (115, 122, 'R_T'),\n",
       "    (26, 36, 'R_T'),\n",
       "    (55, 64, 'R_T'),\n",
       "    (129, 136, 'R_T'),\n",
       "    (74, 92, 'R_T')]}),\n",
       " ('baseline will be defined a the last assessment performed on or prior to date of the first dose of study treatment ( or prior to randomization for randomized patient ) .',\n",
       "  {'entities': [(128, 141, 'R_T')]}),\n",
       " ('these numeric value will be evaluated for clinically significant abnormality , but will not be included in calculation of summary statistic .',\n",
       "  {'entities': [(122, 129, 'R_T'), (130, 139, 'R_T')]}),\n",
       " ('in summary statistic the number and percentage of patient corresponding to grade that only include non-quantitative criterion will be displayed a a blank or na ( not assessed ) rather than 0 .',\n",
       "  {'entities': [(25, 46, 'R_T'), (3, 10, 'R_T'), (11, 20, 'R_T')]}),\n",
       " ('ctcae gradingcriteria for creatinine increased –a value can fall into one range based on comparison to upper limit of normal ( uln ) and another range based on comparison to baseline ) , the highest ( worst ) grade would be assigned to that record .',\n",
       "  {'entities': [(74, 79, 'R_T')]}),\n",
       " ('if the laboratory value is evaluable for ctcae criterion grading ( numeric value is present , valid unit and range are present asthe grade 1-4 criterion for a given laboratorytest , then the value is assigned a grade 0 or otr .',\n",
       "  {'entities': [(109, 114, 'R_T')]}),\n",
       " ('each criterion will be summarized separately .',\n",
       "  {'entities': [(23, 33, 'R_T')]}),\n",
       " ('for ctcae term that can be derived using one of several laboratory test , the maximum postbaselinegrade for a given patient and ctcae term will be the maximum across all possible laboratory test .',\n",
       "  {'entities': [(78, 85, 'R_T')]}),\n",
       " ('in the unlikely event that for a given patient , clinically significant abnormality are noted in both direction ( e.g. , > ulnand < lower limit of normal ( lln ) ) , then both abnormality are counted.summaries at scheduled timepoints will consider only central laboratory data ; however summary overall will consider both central and local laboratory data .',\n",
       "  {'entities': [(287, 294, 'R_T')]}),\n",
       " ('the ratio of test result over the ulnwill be calculated and classified for these three parameter during the on-treatment period .',\n",
       "  {'entities': [(4, 9, 'R_T'), (87, 96, 'R_T'), (45, 55, 'R_T')]}),\n",
       " ('summary of liver function test will include the following category .',\n",
       "  {'entities': [(0, 7, 'R_T')]}),\n",
       " ('the number and percentage of patient with each of the following during the on-treatment period will be summarized by treatment arm : \\uf0b7 alt ≥ 3×uln , alt ≥ 5xuln , alt ≥ 10×uln , alt ≥ 20×uln \\uf0b7 ast ≥ 3×uln , ast ≥ 5xuln , ast ≥ 10×uln , ast ≥ 20×uln \\uf0b7 ( alt or ast ) ≥ 3×uln , ( alt or ast ) ≥ 5×uln , ( alt or ast ) ≥ 10×uln , ( alt or ast ) ≥ 20×uln \\uf0b7 tbili ≥ 2×uln \\uf0b7 concurrent alt ≥ 3×uln and tbili ≥ 2×uln \\uf0b7 concurrent ast ≥ 3×uln and tbili ≥ 2×uln \\uf0b7 concurrent ( alt or ast ) ≥ 3×uln and tbili ≥ 2×uln\\uf0b7 concurrent ( alt or ast ) ≥ 3×uln and tbili ≥ 2×uln and alp ≤ 2×uln or missing concurrent measurement are those occurring on the same date .',\n",
       "  {'entities': [(4, 25, 'R_T'), (103, 113, 'R_T')]}),\n",
       " ('liver function elevation and possible hy ’ s law case will be summarized using frequency count and percentage .',\n",
       "  {'entities': [(99, 109, 'R_T'), (79, 94, 'R_T'), (62, 72, 'R_T')]}),\n",
       " ('an evaluation of drug-induced serious hepatotoxicity ( edish ) plot will also be created , with different symbol for different treatment arm , by graphically displaying \\uf0b7 peak serum alt ( /uln ) v peak total bilirubin ( /uln ) including reference line at alt=3×uln and total bilirubin=2×uln .',\n",
       "  {'entities': [(146, 157, 'R_F'), (63, 67, 'R_F')]}),\n",
       " ('in addition , a listing of all tbili , alt , ast and alp value for patient with a postbaseline tbili ≥ 2×uln , alt≥ 3×uln or ast ≥ 3×uln will be provided .',\n",
       "  {'entities': [(16, 23, 'R_L')]}),\n",
       " ('thenumberandpercentage ofpatients with thefollowingvital signchanges will be presented.the definition of potentiallyclinicallysignificant abnormalitiesareshown in table 10 .',\n",
       "  {'entities': [(163, 168, 'R_T')]}),\n",
       " ('table 10 .', {'entities': [(0, 5, 'R_T')]}),\n",
       " ('potentiallyclinicallysignificantabnormalitiesinvitalsigns parameter criteriaforpotentiallyclinicallysignificantabnormalities systolicbloodpressure absoluteresult > 180 mmhg andincrease from baseline ≥40 mmhg absoluteresult < 90 mmhg and decrease from baseline > 30 mmhg diastolic bloodpressure absoluteresult > 110 mmhg andincrease from baseline ≥30 mmhg absoluteresult < 50 mmhg and decrease from baseline > 20 mmhg ≥ 20 mm hg increase from baseline heart rate absolute result > 120 bpm and increase from baseline > 30 bpm absolute result < 50 bpm and decrease from baseline > 20 bpmtable 10 .',\n",
       "  {'entities': [(58, 67, 'R_T')]}),\n",
       " ('potentiallyclinicallysignificantabnormalitiesinvitalsigns parameter criteriaforpotentiallyclinicallysignificantabnormalities weight > 10 % decrease from baseline 7 .',\n",
       "  {'entities': [(58, 67, 'R_T'), (125, 131, 'R_T')]}),\n",
       " ('if at least 3 participant achieve an objective response and subsequently have an event , dor will be estimated using the same kaplan-meier method a described for pfs in section 6.2.4 and displayed graphically where appropriate .',\n",
       "  {'entities': [(197, 208, 'R_F')]}),\n",
       " ('if at least 3 participant achieve an objective response and subsequently have an event , dor will be estimated using the same kaplan-meier method a described for pfs in section 6.2.4 and displayed graphically where appropriate .',\n",
       "  {'entities': [(197, 208, 'R_F')]}),\n",
       " ('kaplan-meier estimate ( product-limit estimate ) will be presented and displayed graphically where appropriate , together with a summary of associated statistic including the median pfs time with 2-sided 95 % ci if at least 3 participant achieve a scr/cr and subsequently have an event , docr will be estimated using the same kaplan-meier method a described for dor in section 6.2.5 and displayed graphically where appropriate o time will be estimated using the same kaplan-meier method and displayed graphically a described for pfs in section 6.2.4 .',\n",
       "  {'entities': [(204, 211, 'R_T'),\n",
       "    (175, 181, 'R_T'),\n",
       "    (151, 160, 'R_T'),\n",
       "    (129, 136, 'R_T'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (144, 146, 'R_T'),\n",
       "    (81, 92, 'R_F')]}),\n",
       " ('an evaluation of drug-induced serious hepatotoxicity ( edish ) plot will also be created , with different symbol for different cohort , by graphically displaying a waterfall plot of maximum percent reduction in the sum of longest diameter for non-nodal lesion and short axis for nodal lesion from baseline will be created by treatment group .',\n",
       "  {'entities': [(164, 178, 'R_F'),\n",
       "    (139, 150, 'R_F'),\n",
       "    (215, 221, 'R_T'),\n",
       "    (182, 189, 'R_T'),\n",
       "    (63, 67, 'R_F')]}),\n",
       " ('a kaplan-meier plot for pfs follow-up duration will also be generated to ass the followup time in the treatment group reversing the pfs censoring and event indicator .',\n",
       "  {'entities': [(2, 19, 'R_F')]}),\n",
       " ('a waterfall plot of maximum percent decrease in psa value from baseline will be created .',\n",
       "  {'entities': [(20, 27, 'R_T'), (2, 16, 'R_F')]}),\n",
       " ('a waterfall plot of maximum percent decrease in ctc count from baseline will be created for all patient with ctc count ≥ 5 ctc per 7.5 ml at baseline .',\n",
       "  {'entities': [(20, 27, 'R_T'), (2, 16, 'R_F')]}),\n",
       " ('a waterfall plot of maximum percent decrease in ca-125 value from baseline will be created .',\n",
       "  {'entities': [(20, 27, 'R_T'), (2, 16, 'R_F')]}),\n",
       " ('the plot will display the best percentage change from baseline in ca-125 value for each patient with a baseline assessment and at least one post-baseline assessment .',\n",
       "  {'entities': [(4, 8, 'R_F'), (31, 41, 'R_T')]}),\n",
       " ('linear-linear plot of mean or median plasma concentration by nominal time for avelumab and talazoparib will be presented for pk sampling day by cycle and study day .',\n",
       "  {'entities': [(30, 36, 'R_T'), (14, 18, 'R_F'), (22, 26, 'R_T')]}),\n",
       " ('the trough concentration for avelumab and talazoparib will be plotted using a box whisker plot by cycle and day in order to ass the attainment of steady state .',\n",
       "  {'entities': [(62, 69, 'R_F')]}),\n",
       " ('individual data point , the geometric mean , and the median of the parameter in each treatment will be overlaid on the box plot .',\n",
       "  {'entities': [(28, 42, 'R_T'),\n",
       "    (67, 76, 'R_T'),\n",
       "    (53, 59, 'R_T'),\n",
       "    (123, 127, 'R_F')]}),\n",
       " ('line chart depicting the mean and mean change with standard error ( se ) bar over time will be provided overall and for each cohort .',\n",
       "  {'entities': [(0, 10, 'R_F'), (25, 29, 'R_T'), (51, 65, 'R_T')]}),\n",
       " ('for endpoint that require graphical summary , plot of mean +/- standard error will be generated for the observed data by treatment group , and plot of ls-mean +/- standard error will be generated for ( percent ) change from baseline over time by treatment group .',\n",
       "  {'entities': [(36, 43, 'R_T'),\n",
       "    (63, 77, 'R_T'),\n",
       "    (46, 50, 'R_F'),\n",
       "    (54, 58, 'R_T')]}),\n",
       " ('l mean plot of change from baseline in egfr over time ( in year ) by treatment group will be generated .',\n",
       "  {'entities': [(7, 11, 'R_F'), (2, 6, 'R_T')]}),\n",
       " ('kaplan-meier estimate ( time-to-event distirbutions ) will be presented and displayed graphically where appropriate in addition , box and whisker plot for individual patient parameter auc\\uf074 , cmax , and ctrough by dose and scheduled visit a well a for dose-normalized auc\\uf074 , cmax , and ctrough by scheduled visit maybe be presented and overlaid with geometric mean .',\n",
       "  {'entities': [(130, 150, 'R_F'),\n",
       "    (86, 97, 'R_F'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (174, 183, 'R_T'),\n",
       "    (349, 363, 'R_T')]}),\n",
       " ('kaplan-meier curve will be used to estimate the time-to-event distribution .',\n",
       "  {'entities': [(0, 18, 'R_F'), (35, 43, 'R_T'), (62, 74, 'R_T')]}),\n",
       " ('an overview forest plot of rpfs based on bicr assessment by the following subgroup will be presented a similar forest plot based on investigator assessment will also be provided .',\n",
       "  {'entities': [(12, 23, 'R_F')]}),\n",
       " ('analysis of the eq-5d health index will consist of descriptive statistic on mean and change from baseline , overall change from baseline using a longitudinal mixed effect model , and graphical display of mean and change from baseline over time .',\n",
       "  {'entities': [(63, 72, 'R_T'), (76, 80, 'R_T')]}),\n",
       " ('a graphical display of mean over time a well a mean change from baseline over time will also be provided .',\n",
       "  {'entities': [(23, 27, 'R_T')]}),\n",
       " ('otherwise only listing will be provided .',\n",
       "  {'entities': [(15, 22, 'R_L')]}),\n",
       " ('aes not considered treatment emergent will be flagged in data listing .',\n",
       "  {'entities': [(62, 69, 'R_L')]}),\n",
       " ('in addition , the following listing of all tbili , alt , ast and alp value will be provided vital sign data will be listed .',\n",
       "  {'entities': [(116, 122, 'R_L'), (28, 35, 'R_L')]}),\n",
       " ('all ecg assessment will be listed , and those collected outside the on-treatment period will be flagged in the listing safety data collected after the on-treatment period a described above will be listed but not summarized .',\n",
       "  {'entities': [(111, 118, 'R_L'), (212, 222, 'R_T'), (27, 33, 'R_L')]}),\n",
       " ('pharmacokinetic parameter for avelumab and talazoparib will be listed and summarized by cycle and study day using descriptive statistic ( n , mean , sd , % cv , median , minimum , maximum , geometric mean , and it associated % cv , and 95 % ci ) .',\n",
       "  {'entities': [(236, 243, 'R_T'),\n",
       "    (10, 11, 'R_T'),\n",
       "    (161, 167, 'R_T'),\n",
       "    (218, 220, 'R_T'),\n",
       "    (63, 69, 'R_L'),\n",
       "    (142, 146, 'R_T'),\n",
       "    (16, 25, 'R_T'),\n",
       "    (190, 204, 'R_T'),\n",
       "    (149, 151, 'R_T'),\n",
       "    (74, 84, 'R_T'),\n",
       "    (180, 187, 'R_T'),\n",
       "    (170, 177, 'R_T'),\n",
       "    (126, 135, 'R_T'),\n",
       "    (156, 158, 'R_T')]}),\n",
       " ('the listing of demographic and baseline characteristic will include the following information : patient identifier , treatment group , age , sex , race , ethnicity , height ( cm ) , weight ( kg ) , bmi ( kg/m2 ) , and ecog performance status .',\n",
       "  {'entities': [(182, 188, 'R_T'), (4, 11, 'R_L')]}),\n",
       " ('listing of disease history will be provided with all relevant data ( a collected on the ‘ primary diagnosis ’ ecrf page ) and derived variable a above .',\n",
       "  {'entities': [(134, 142, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('a listing of prior medication and a listing of concomitant medication will be created with the relevant information collected on the ‘ general concomitant medication ’ ecrf page .',\n",
       "  {'entities': [(2, 9, 'R_L')]}),\n",
       " ('a listing of pre-medications will be created with the relevant information collected on the ‘ pre- medication treatment ’ ecrf page .',\n",
       "  {'entities': [(2, 9, 'R_L')]}),\n",
       " ('all concurrent procedure , which were undertaken any time during the on-treatment period , will be listed according to the ecrf page ‘ general non-drug treatment ’ .',\n",
       "  {'entities': [(99, 105, 'R_L')]}),\n",
       " ('anti-cancer treatment will be provided in a data listing with data retrieved from ‘ follow-up cancer therapy ’ , ‘ concomitant radiation therapy ’ , ‘ follow-up radiation therapy ’ , ‘ on-study anti-cancer surgery ’ , and ‘ follow-up surgery ’ ecrf page .',\n",
       "  {'entities': [(49, 56, 'R_L')]}),\n",
       " ('the ae listing will include all aes ( whether treatment-emergent or not ) .',\n",
       "  {'entities': [(7, 14, 'R_L')]}),\n",
       " ('in addition , date and cause of death will be provided in individual patient data listing together with selected dosing information ( study treatment received , date of first / last administration , dose ) and will include the following information : the listing of all iraes will also be provided with the relevant information with a flag for iraes with onset outside of the on-treatment period .',\n",
       "  {'entities': [(82, 89, 'R_L')]}),\n",
       " ('the listing of all irrs will also be provided with the relevant information with a flag for irrs with onset outside of the on-treatment period .',\n",
       "  {'entities': [(4, 11, 'R_L')]}),\n",
       " ('the listing of laboratory result will be provided for all laboratory parameter .',\n",
       "  {'entities': [(4, 11, 'R_L'), (69, 78, 'R_T')]}),\n",
       " ('the listing will be sorted by parameter and assessment date or visit for each patient .',\n",
       "  {'entities': [(30, 39, 'R_T'), (4, 11, 'R_L')]}),\n",
       " ('infusion data will be listed for each subject .',\n",
       "  {'entities': [(22, 28, 'R_L')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('the percentage of participant with positive ada will be summarized .',\n",
       "  {'entities': [(4, 14, 'R_T'), (56, 66, 'R_T')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('they will be summarized using the on-study approach a defined in section 3.5.1 .',\n",
       "  {'entities': [(13, 23, 'R_T')]}),\n",
       " ('the ontreatment 28-day approach will only be presented a a flag in listing .',\n",
       "  {'entities': [(67, 74, 'R_L')]}),\n",
       " ('pre-dose ( trough ) pk concentration will be listed using pk concentration set .',\n",
       "  {'entities': [(45, 51, 'R_L')]}),\n",
       " ('the “ on-treatment+28-day ” approach will only be presented a a flag in listing .',\n",
       "  {'entities': [(72, 79, 'R_L')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated laboratory test value for individual subject will be listed .',\n",
       "  {'entities': [(12, 19, 'R_T'), (148, 154, 'R_L'), (0, 7, 'R_L')]}),\n",
       " ('all laboratory data listing and summary will be based on safety analysis set using the on-treatment+5-day approach .',\n",
       "  {'entities': [(32, 39, 'R_T'), (20, 27, 'R_L')]}),\n",
       " ('laboratory test value for individual subject will be listed .',\n",
       "  {'entities': [(53, 59, 'R_L')]}),\n",
       " ('all planned individual patient ’ plasma concentration data will be listed ( pharmacokinetic population ) .',\n",
       "  {'entities': [(67, 73, 'R_L')]}),\n",
       " ('pk sample obtained beyond 10 % of the planned time will be included in the listing and could be included in the calculation of pk parameter mutation status ( where available ) and starting dose will be provided in data listing .',\n",
       "  {'entities': [(75, 82, 'R_L'), (130, 139, 'R_T'), (3, 9, 'R_T')]}),\n",
       " ('if a patient meet multiple definition for censoring at the same visit , the list will be used to define the hierarchy .',\n",
       "  {'entities': [(76, 80, 'R_L')]}),\n",
       " ('additionally adverse event listing will consider the dose at the time of the start of the event .',\n",
       "  {'entities': [(27, 34, 'R_L')]}),\n",
       " ('date and cause of death will be provided in individual patient data listing with selected dosing information ( study treatment received , date of first / last administration , dose , etc . )',\n",
       "  {'entities': [(68, 75, 'R_L')]}),\n",
       " ('aes not considered treatment-emergent will be flagged in data listing .',\n",
       "  {'entities': [(62, 69, 'R_L')]}),\n",
       " ('the number and percentage of patient within each category ( medication therapy , radiation therapy , and surgery ) will be provided by treatment arm for the part 2 itt population .',\n",
       "  {'entities': [(4, 25, 'R_T')]}),\n",
       " ('subsequent anticancer therapy and procedure will be listed for part 1 and part 2 .',\n",
       "  {'entities': [(52, 58, 'R_L')]}),\n",
       " ('concomitant medication in will be listed for part 1 and part 2 .',\n",
       "  {'entities': [(34, 40, 'R_L')]}),\n",
       " ('for part 1 , select data may be listed instead of summarized .',\n",
       "  {'entities': [(32, 38, 'R_L'), (50, 60, 'R_T')]}),\n",
       " ('all summary and listing for the aes will be generated separately for maternal and infant participant .',\n",
       "  {'entities': [(4, 11, 'R_T'), (16, 23, 'R_L')]}),\n",
       " ('descriptive summary ( count and percentage ) and listing based on the safety population will be provided in accordance with the pfizer reporting standard .',\n",
       "  {'entities': [(12, 19, 'R_T'),\n",
       "    (49, 56, 'R_L'),\n",
       "    (32, 42, 'R_T'),\n",
       "    (145, 153, 'R_T')]}),\n",
       " ('all summary and listing for these data will be generated separately for maternal and infant participant .',\n",
       "  {'entities': [(4, 11, 'R_T'), (16, 23, 'R_L')]}),\n",
       " ('descriptive summary and data listing will be generated for the obstetric examination finding and pregnancy outcome .',\n",
       "  {'entities': [(12, 19, 'R_T'), (29, 36, 'R_L')]}),\n",
       " ('the summary and listing for these data will be generated only for maternal participant .',\n",
       "  {'entities': [(4, 11, 'R_T'), (16, 23, 'R_L')]}),\n",
       " ('all laboratory data listing and summary will be based on safety analysis set using the on-treatment+5-day approach .',\n",
       "  {'entities': [(32, 39, 'R_T'), (20, 27, 'R_L')]}),\n",
       " ('the ontreatment+ 28-day approach will only be presented a a flag in listing .',\n",
       "  {'entities': [(68, 75, 'R_L')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('the analysis will consist of the following descriptive statistic : mean , standard deviation , median , minimum , and maximum observed abr , a well a the number of non-missing observation .',\n",
       "  {'entities': [(67, 71, 'R_T'),\n",
       "    (95, 101, 'R_T'),\n",
       "    (118, 125, 'R_T'),\n",
       "    (104, 111, 'R_T'),\n",
       "    (55, 64, 'R_T'),\n",
       "    (74, 92, 'R_T')]}),\n",
       " ('additionally , abrs will be summarized by bleed type ( eg , spontaneous or traumatic ) and by bleed location ( eg , joint , soft tissue/muscle ) .',\n",
       "  {'entities': [(28, 38, 'R_T')]}),\n",
       " ('the analysis of annualized tfc and dose by weight ( iu/kg ) will consist of the following descriptive statistic : mean , standard deviation , median , minimum , and maximum observed annualized tfc , a well a the number of non-missing observation .',\n",
       "  {'entities': [(142, 148, 'R_T'),\n",
       "    (151, 158, 'R_T'),\n",
       "    (165, 172, 'R_T'),\n",
       "    (43, 49, 'R_T'),\n",
       "    (114, 118, 'R_T'),\n",
       "    (102, 111, 'R_T'),\n",
       "    (121, 139, 'R_T')]}),\n",
       " ('additionally , this endpoint will be summarized a a categorical variable with category 1 , 2 , 3 , 4 , or > 4 infusion needed to treat the blead .',\n",
       "  {'entities': [(64, 72, 'R_T'), (37, 47, 'R_T')]}),\n",
       " ('the number of subject contributing data ( ie , the number of subject with any new bleed ) for the analysis will also be reported .',\n",
       "  {'entities': [(120, 128, 'R_T')]}),\n",
       " ('the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(4, 25, 'R_T'), (180, 190, 'R_T')]}),\n",
       " ('descriptive summary of concomitant medication and treatment will be reported .',\n",
       "  {'entities': [(12, 19, 'R_T'), (68, 76, 'R_T')]}),\n",
       " ('adverse event the number ( % ) of subject who experienced teaes will be reviewed and summarized by relatedness to the study drug and by maximum severity grade .',\n",
       "  {'entities': [(136, 143, 'R_T'), (85, 95, 'R_T')]}),\n",
       " ('descriptive statistic ( number and frequency ) will be provided for all adverse event summary .',\n",
       "  {'entities': [(86, 93, 'R_T'), (35, 44, 'R_T'), (12, 21, 'R_T')]}),\n",
       " ('descriptive statistic of observed value and change from baseline for vital sign at each visit , including height ( cm ) , weight ( kg ) , blood pressure ( mmhg ) , heart rate ( beats/min ) , and body temperature ( °f ) , a well a abnormal finding from physical examination , will be presented .',\n",
       "  {'entities': [(183, 186, 'R_T'), (122, 128, 'R_T'), (12, 21, 'R_T')]}),\n",
       " ('bar graph of prevaccination and 1-month-postvaccination neutralizing gmt will be produced for each vaccine group .',\n",
       "  {'entities': [(0, 9, 'R_F')]}),\n",
       " ('for each group , n , mean , median , minimum , and maximum will be presented by vaccine group for the following variable .',\n",
       "  {'entities': [(21, 25, 'R_T'),\n",
       "    (37, 44, 'R_T'),\n",
       "    (51, 58, 'R_T'),\n",
       "    (17, 18, 'R_T'),\n",
       "    (112, 120, 'R_T'),\n",
       "    (28, 34, 'R_T')]}),\n",
       " ('for aes classified a tier2 event , difference in proportion and associated 2-sided 95 % ci between the vaccine group andtheplacebo group will be presented .',\n",
       "  {'entities': [(83, 90, 'R_T'), (68, 70, 'R_T')]}),\n",
       " ('gmt of the rsv a–and rsv b–neutralizing antibody titer at each available time point will be descriptively summarized for each vaccine group , along with associated 2-sided 95 % ci .',\n",
       "  {'entities': [(172, 179, 'R_T'), (129, 131, 'R_T'), (92, 116, 'R_T')]}),\n",
       " ('bar graph of prevaccination and 1-month-postvaccination neutralizing gmt will be produced for each vaccine group .',\n",
       "  {'entities': [(0, 9, 'R_F')]}),\n",
       " ('or each individual , the combined rsva/b–neutralizing gmt is the geometric mean of the of rsva–and rsv b–neutralizing titer .',\n",
       "  {'entities': [(65, 79, 'R_T')]}),\n",
       " ('the proportion of infant participant with lrti caused by each of rsv a and rsv b a determined by rt-pcr , along with the associated exact 2-sided 95 % ci using the clopper-pearson method , will be summarized in the same way .',\n",
       "  {'entities': [(146, 153, 'R_T'), (30, 32, 'R_T'), (197, 207, 'R_T')]}),\n",
       " ('a correlation scatterplot will be generated with the maternal titer on the x-axis and the infant blood titer on the y-axis .',\n",
       "  {'entities': [(2, 13, 'R_T')]}),\n",
       " ('baseline summary for maternal participant for each vaccine group , descriptive summary statistic r_t for demographic characteristic ( ageat vaccination , sex , race and ethnicity ) , current substance use , and obstetric historyas described in section 3.5.6will be generated for each vaccine group based on the safety population .',\n",
       "  {'entities': [(87, 96, 'R_T'), (9, 16, 'R_T')]}),\n",
       " ('the number and proportion of participant with at least 1 medical history pt , arranged by soc , will be tabulated for each vaccine group .',\n",
       "  {'entities': [(4, 25, 'R_T'), (104, 113, 'R_T')]}),\n",
       " ('the estimated hazard ratio ( hr ) , 95 % confidence interval and p-value for hr comparing lotiglipron to placebo will be presented .',\n",
       "  {'entities': [(41, 60, 'R_T'), (21, 26, 'R_T'), (65, 72, 'R_T')]}),\n",
       " ('the above cph analysis and km curve will be repeated without pooling lotiglipron treatment group and the resulting statistic comparing lotiglipron to placebo will be presented in the same table/figure output but treated a nominal .',\n",
       "  {'entities': [(27, 35, 'R_F'),\n",
       "    (115, 124, 'R_T'),\n",
       "    (188, 193, 'R_T'),\n",
       "    (194, 200, 'R_F')]}),\n",
       " ('the tipping point analysis ( section 5.3.1 ) will first impute the missing data based on all observed time to event/censoring data in the pooled lotiglipron group under the car/mar assumption ( ie , \\U0010000a is defined a the hazard ratio comparing missing data to observed data in the same treatment group , with \\U0010000a = 1 corresponding to the car assumption ) , and then in the direction towards a more and more conservative mnar assumption ( ie , by gradually increasing \\U0010000a ) , the tipping point will be identified a the smallest \\U0010000a ( \\U0010000a > 1 ) that overturn the conclusion of significance .',\n",
       "  {'entities': [(225, 230, 'R_T'), (564, 576, 'R_T')]}),\n",
       " ('p-values corresponding to each \\U0010000a of this line search will be tabulated and the tipping point if identifiable will be called out in the output .',\n",
       "  {'entities': [(61, 70, 'R_T')]}),\n",
       " ('the same statistic will be reported a described for the main analysis .',\n",
       "  {'entities': [(27, 35, 'R_T'), (9, 18, 'R_T')]}),\n",
       " ('they will be summarized using the on-study approach .',\n",
       "  {'entities': [(13, 23, 'R_T')]}),\n",
       " ('the sample size , mean , standard deviation , median , minimum , and maximum at the baseline and post-baseline visit ( converted to year from the first dose ) for observed egfr value and change from baseline will be presented for each treatment group .',\n",
       "  {'entities': [(46, 52, 'R_T'),\n",
       "    (55, 62, 'R_T'),\n",
       "    (69, 76, 'R_T'),\n",
       "    (4, 15, 'R_T'),\n",
       "    (25, 43, 'R_T'),\n",
       "    (18, 22, 'R_T')]}),\n",
       " ('in addition , the l mean of rate of change in egfr per year by treatment group and the difference between lotiglipron and placebo along with 95 % ci and p-value will be presented .',\n",
       "  {'entities': [(153, 160, 'R_T'), (20, 24, 'R_T'), (141, 148, 'R_T')]}),\n",
       " ('the sample size , the number ( % ) of subject achieving the goal will be presented for each treatment group .',\n",
       "  {'entities': [(4, 15, 'R_T')]}),\n",
       " ('adjusted odds ratio ( or ) along with 95 % ci and p-values comparing each lotiglipron group to placebo will be presented .',\n",
       "  {'entities': [(38, 45, 'R_T'), (9, 19, 'R_T')]}),\n",
       " ('in addition , change from baseline will also be summarized by domain , treatment group and visit .',\n",
       "  {'entities': [(48, 58, 'R_T')]}),\n",
       " ('pre-dose ( trough ) pk concentration will be listed using pk concentration set .',\n",
       "  {'entities': [(45, 51, 'R_L')]}),\n",
       " ('in each category , sample size , number of event , study exposure and hazard rate will be presented for each treatment group .',\n",
       "  {'entities': [(19, 30, 'R_T')]}),\n",
       " (\"extent of exposure to study intervention will be summarized using summary statistic ( n , mean , median , standard deviation , and range ) and frequency n ( % ) for categorized `` '' number of week on treatment/study '' '' by treatment group .\",\n",
       "  {'entities': [(143, 152, 'R_T'),\n",
       "    (97, 103, 'R_T'),\n",
       "    (74, 83, 'R_T'),\n",
       "    (90, 94, 'R_T'),\n",
       "    (106, 124, 'R_T'),\n",
       "    (4, 5, 'R_T'),\n",
       "    (49, 59, 'R_T'),\n",
       "    (66, 73, 'R_T'),\n",
       "    (131, 136, 'R_T')]}),\n",
       " ('subject taking specific concomitant medication ( not restricting to aha therapy , cv medication ) will be summarized at baseline and end of study , using the who-drug dictionary .',\n",
       "  {'entities': [(106, 116, 'R_T'), (82, 84, 'R_T')]}),\n",
       " ('risk difference of pooled lotiglipron v placebo will be primarily reported .',\n",
       "  {'entities': [(66, 74, 'R_T')]}),\n",
       " ('for tier 1 aes , incidence rate by treatment group , estimated risk difference comparing lotiglipron to placebo along with 95 % confidence interval and p-value will be reported .',\n",
       "  {'entities': [(152, 159, 'R_T'), (128, 147, 'R_T'), (168, 176, 'R_T')]}),\n",
       " ('aes will be displayed in alphabetical order of soc and pt and will be summarized using the “ on-study ” approacheas .',\n",
       "  {'entities': [(70, 80, 'R_T')]}),\n",
       " ('all laboratory data listing and summary will be based on safety analysis set using the on-treatment+5-day approach .',\n",
       "  {'entities': [(32, 39, 'R_T'), (20, 27, 'R_L')]}),\n",
       " ('the medical history summary is based on the safety population .',\n",
       "  {'entities': [(20, 27, 'R_T')]}),\n",
       " ('these summary will be generated separately for maternal and infant participant .',\n",
       "  {'entities': [(6, 13, 'R_T')]}),\n",
       " ('the number and proportion of participant who were randomized , were vaccinated , and had blood drawn withinthe protocol-specified time frame , and outside the specified window , will be tabulated by vaccinegroup .',\n",
       "  {'entities': [(186, 195, 'R_T'), (4, 25, 'R_T')]}),\n",
       " ('these summary will be generated only for maternal participant the summary and listing for these data will be generated only for maternal participant .',\n",
       "  {'entities': [(6, 13, 'R_T'), (78, 85, 'R_L')]}),\n",
       " ('physical examination , including vital sign descriptive summary ( count and percentage ) and listing based on the safety population will be provided in accordance with the pfizer reporting standard .',\n",
       "  {'entities': [(56, 63, 'R_T'),\n",
       "    (93, 100, 'R_L'),\n",
       "    (76, 86, 'R_T'),\n",
       "    (189, 197, 'R_T')]}),\n",
       " ('descriptive summary statistic for each group , number of participant with obstetric complication .',\n",
       "  {'entities': [(12, 19, 'R_T'), (20, 29, 'R_T')]}),\n",
       " ('for each group , number and proportion of participant with each birth outcome will be presented by vaccine group .',\n",
       "  {'entities': [(17, 38, 'R_T')]}),\n",
       " ('bar graph of prevaccination and 1-month-postvaccination neutralizing gmt will be produced for each vaccine group .',\n",
       "  {'entities': [(0, 9, 'R_F')]}),\n",
       " ('clinical laboratory abnormality will be summarized with respect to prespecified criterion determined from normal range and abnormality cutoff considered to be clinically meaningful , following pfizer standard .',\n",
       "  {'entities': [(113, 118, 'R_T'), (40, 50, 'R_T'), (200, 208, 'R_T')]}),\n",
       " ('specifically the following liver test abnormality will be reported .',\n",
       "  {'entities': [(58, 66, 'R_T')]}),\n",
       " ('shift table will be generated for hba1c , fpg , alt , ast , amylase , lipase , uacr , sbp , dbp , heart rate , body weight , egfr , bun , serum creatinine using the worst on-treatment assessment approach .',\n",
       "  {'entities': [(116, 122, 'R_T'), (6, 11, 'R_T')]}),\n",
       " ('to support the assessment of local reaction , additional endpoint will be summarized with all analysis time point ( within 14 day after vaccination 1 and within 14 day after vaccination 2 ) , analysis population ( primary study cohort - stage 1 , primary study cohort - stage 2 , and rsv vaccine month-0 , month-2 cohort ) , analysis methodology , and appropriate reporting result .',\n",
       "  {'entities': [(74, 84, 'R_T')]}),\n",
       " ('figure : bar chart with the proportion of subject reporting each local reaction within 14 day after vaccination will be plotted for each vaccine group .',\n",
       "  {'entities': [(0, 6, 'R_F'), (120, 127, 'R_F'), (9, 18, 'R_F')]}),\n",
       " ('the bar will be stacked by maximum severity to highlight the proportion of subject by severity .',\n",
       "  {'entities': [(27, 34, 'R_T')]}),\n",
       " ('to support the assessment of systemic event , similar endpoint a above will be summarized for the primary study cohort - stage 2 within 14 day after vaccination 2 ; a well a for the rsv vaccine month-0 , month-2 cohort within 14 day after vaccination 1 and within 14 day after vaccination 2 .',\n",
       "  {'entities': [(79, 89, 'R_T')]}),\n",
       " ('figure : bar chart with the proportion of subject reporting each systemic event within 14 day after vaccination will be plotted for each vaccine group .',\n",
       "  {'entities': [(0, 6, 'R_F'), (120, 127, 'R_F'), (9, 18, 'R_F')]}),\n",
       " ('to support the assessment of aes , similar endpoint a above will be summarized for the primary study cohort - stage 2 within 1 month after vaccination 2 ; a well a for the rsv vaccine month-0 , month-2 cohort within 1 month after each vaccination and from vaccination 1 through 1 month after vaccination 2 .',\n",
       "  {'entities': [(68, 78, 'R_T')]}),\n",
       " ('to support the assessment of aes , additional endpoint by category ( related ae , severe ae , sae , mae , immediate ae , ae leading to withdrawal , ae of specific interest ) , a defined in section 3.1.4 , will be summarized with all analysis time point ( within 1 month after vaccination 1 and within 1 month after vaccination 2 ) , analysis population ( primary study cohort - stage 1 , primary study cohort - stage 2 , and rsv vaccine month-0 , month-2 cohort ) , analysis methodology , and appropriate reporting result .',\n",
       "  {'entities': [(213, 223, 'R_T')]}),\n",
       " ('gmt before and 1 month after vaccination 1 , and associated 2-sided 95 % ci , will be summarized by vaccine group for both rsv a– and rsv b–neutralizing antibody titer .',\n",
       "  {'entities': [(68, 75, 'R_T'), (86, 96, 'R_T'), (32, 34, 'R_T')]}),\n",
       " ('also , gmfrs from before to 1 month after vaccination 1 , and associated 2-sided 95 % ci , will be summarized by vaccine group for both rsv a– and rsv b–neutralizing antibody titer .',\n",
       "  {'entities': [(99, 109, 'R_T'), (81, 88, 'R_T'), (45, 47, 'R_T')]}),\n",
       " ('figure : rcdcs for rsv a– and rsv b–neutralizing antibody titer for the 2 time point ( before vaccination 1 and 1 month after vaccination 1 ) will be generated by vaccine group .',\n",
       "  {'entities': [(0, 6, 'R_F')]}),\n",
       " ('for the primary study cohort - stage 1 , gmt at all other applicable visit after vaccination 1 but before vaccination 2 will be summarized along with associated 2-sided 95 % ci , by vaccine group , for both rsv a– and rsv b–neutralizing antibody titer .',\n",
       "  {'entities': [(169, 176, 'R_T'), (84, 86, 'R_T'), (128, 138, 'R_T')]}),\n",
       " ('similarly , for the rsv vaccine month-0 , month-2 cohort , gmt at all applicable visit will be summarized with 2-sided 95 % ci .',\n",
       "  {'entities': [(95, 105, 'R_T'), (27, 29, 'R_T'), (119, 126, 'R_T')]}),\n",
       " ('for the primary study cohort - stage 2 , gmt at all applicable visit ( including visit in stage 1 and stage 2 ) will be summarized with 2-sided 95 % ci .',\n",
       "  {'entities': [(144, 151, 'R_T'), (120, 130, 'R_T')]}),\n",
       " ('additionally , all fold rise specified will be summarized with gmfrs and associated 2-sided 95 % ci .',\n",
       "  {'entities': [(92, 99, 'R_T'), (47, 57, 'R_T'), (32, 34, 'R_T')]}),\n",
       " ('for the remaining 2 cohort ( primary study cohort - stage 2 and rsv vaccine month-0 , month-2 cohort ) , rcdcs will be plotted for prevaccination and 1-month postvaccination visit only .',\n",
       "  {'entities': [(119, 126, 'R_F')]}),\n",
       " ('nt gmt kinetics will be plotted across all visit for each cohort .',\n",
       "  {'entities': [(24, 31, 'R_F')]}),\n",
       " ('gmt before and 1 month after vaccination 1 and associated 2-sided 95 % ci will be summarized by vaccine group for each influenza strain tested .',\n",
       "  {'entities': [(66, 73, 'R_T'), (32, 34, 'R_T'), (82, 92, 'R_T')]}),\n",
       " ('also , gmfrs from before to 1 month after vaccination 1 and associated 2-sided 95 % ci will be summarized by vaccine group for each strain tested .',\n",
       "  {'entities': [(95, 105, 'R_T'), (79, 86, 'R_T'), (45, 47, 'R_T')]}),\n",
       " ('figure : rcdcs for each influenza strain testing at the 2 time point ( before vaccination 1 and 1 month after vaccination 1 ) will be generated by vaccine group .',\n",
       "  {'entities': [(0, 6, 'R_F')]}),\n",
       " ('for the primary study cohort - stage 1 , the seroprotection rate before vaccination 1 and 1 month after vaccination 1 , and seroconversion rate from before vaccination 1 to 1 month after vaccination 1 , will be summarized with n , percentage ( % ) , and 2-sided 95 % ci , among the evaluable immunogenicity population .',\n",
       "  {'entities': [(58, 59, 'R_T'),\n",
       "    (231, 241, 'R_T'),\n",
       "    (262, 269, 'R_T'),\n",
       "    (75, 77, 'R_T'),\n",
       "    (211, 221, 'R_T')]}),\n",
       " ('for the primary study cohort - stage 2 , gmt before and 1 month after vaccination 2 and gmfrs from before to 1 month after vaccination 2 will all be descriptively summarized with associated 2-sided 95 % ci by vaccine group for each influenza strain tested .',\n",
       "  {'entities': [(198, 205, 'R_T'), (149, 173, 'R_T'), (73, 75, 'R_T')]}),\n",
       " ('the seroprotection rate before vaccination 2 and 1 month after vaccination 2 , and seroconversion rate from before vaccination 2 to 1 month after vaccination 2 , will be summarized with n , percentage ( % ) , and 2-sided 95 % ci .',\n",
       "  {'entities': [(190, 200, 'R_T'),\n",
       "    (170, 180, 'R_T'),\n",
       "    (17, 18, 'R_T'),\n",
       "    (34, 36, 'R_T'),\n",
       "    (221, 228, 'R_T')]}),\n",
       " ('for each cohort , the igg a and igg b will be descriptively summarized with gmc and associated 2-sided 95 % ci , at each applicable visit among the evaluable immunogenicity population .',\n",
       "  {'entities': [(46, 70, 'R_T'), (103, 110, 'R_T'), (88, 90, 'R_T')]}),\n",
       " ('similarly , for each cohort , the fold rise of igg a and igg b ( defined in section 3.3.2 ) will be descriptively summarized with gmfr and associated 2-sided 95 % ci , at each applicable visit among the evaluable immunogenicity population .',\n",
       "  {'entities': [(158, 165, 'R_T'), (143, 145, 'R_T'), (100, 124, 'R_T')]}),\n",
       " ('for the 1-month postvaccination visit , a gmc summary from the primary study cohort - stage 1 and the rsv vaccine month-0 , month-2 cohort will be presented for each vaccine group together with pooled placebo data .',\n",
       "  {'entities': [(46, 53, 'R_T')]}),\n",
       " ('for each cohort , the endpoint defined in will be summarized with n , percentage ( % ) , and 2-sided 95 % ci , for each applicable visit , among the evaluable immunogenicity population .',\n",
       "  {'entities': [(23, 24, 'R_T'),\n",
       "    (101, 108, 'R_T'),\n",
       "    (70, 80, 'R_T'),\n",
       "    (50, 60, 'R_T')]}),\n",
       " ('for each cohort , at each applicable visit , the ratio will be summarized with geometric mean , along with 2-sided 95 % ci , among the evaluable immunogenicity population .',\n",
       "  {'entities': [(49, 54, 'R_T'),\n",
       "    (63, 73, 'R_T'),\n",
       "    (115, 122, 'R_T'),\n",
       "    (79, 93, 'R_T')]}),\n",
       " ('the proportion of subject reporting a “ current smoker , ” “ ex-smoker , ” and “ never smoked ” will be summarized in a similar way .',\n",
       "  {'entities': [(104, 114, 'R_T')]}),\n",
       " ('the number and percentage of subject with at least 1 diagnosis , overall and at each soc and pt level , may be summarized by vaccine group and for overall subject included in the safety population for each cohort .',\n",
       "  {'entities': [(4, 25, 'R_T'), (111, 121, 'R_T')]}),\n",
       " ('the number and proportion of randomized subject will be included in the subject disposition summary .',\n",
       "  {'entities': [(92, 99, 'R_T'), (4, 25, 'R_T')]}),\n",
       " ('subject excluded from the evaluable immunogenicity and mitt population will also be summarized with reason for exclusion .',\n",
       "  {'entities': [(84, 94, 'R_T')]}),\n",
       " ('the f statistic and p-value for the main effect and interaction will be calculated .',\n",
       "  {'entities': [(20, 27, 'R_T'), (6, 15, 'R_T'), (72, 82, 'R_T')]}),\n",
       " ('the summary will be provided cumulatively for case occurring through 1 , 2 , 3 , 4 , 5 , and 6 month of age , a well a marginally for case occurring in each month interval : 0 to 30 day , 31 to 60 day , 61 to 90 day , 91 to 120 day , 121 to 150 day , and 151 to 180 day .',\n",
       "  {'entities': [(4, 11, 'R_T')]}),\n",
       " ('a correlation scatterplot will be generated with the maternal titer on the x-axis and the infant blood titer on the y-axis .',\n",
       "  {'entities': [(2, 13, 'R_T')]}),\n",
       " ('the number and proportion of randomized participant will be included in the participant disposition summary .',\n",
       "  {'entities': [(100, 107, 'R_T'), (4, 25, 'R_T')]}),\n",
       " ('the number and proportion of participant who were randomized , were vaccinated , and had blood drawn withinthe protocol-specified time frame .',\n",
       "  {'entities': [(4, 25, 'R_T')]}),\n",
       " ('these summary will be generated separately for maternal andinfant participant .',\n",
       "  {'entities': [(6, 13, 'R_T')]}),\n",
       " ('all summary and listing for these data will be generated separately for maternal and infant participant .',\n",
       "  {'entities': [(4, 11, 'R_T'), (16, 23, 'R_L')]}),\n",
       " ('obstetric examination and pregnancy outcome descriptive summary and data listing will be generated for the obstetric examination finding and pregnancy outcome .',\n",
       "  {'entities': [(56, 63, 'R_T'), (73, 80, 'R_L')]}),\n",
       " ('nonstudy vaccine taken after signing the informed consent through the end of the study will be categorized according to the who drug dictionary and may be summarized by vaccine group and for all subject included in the safety population .',\n",
       "  {'entities': [(155, 165, 'R_T')]}),\n",
       " ('in addition , the frequency ( number and percentage ) of participant with bor by bicr in each response category and corresponding 2-sided exact 95 % ci will be summarized : scr ; cr ; vgpr ; pr ; mr ; sd ; pd ; not evaluable ( ne ) /unknown .',\n",
       "  {'entities': [(144, 151, 'R_T'),\n",
       "    (30, 51, 'R_T'),\n",
       "    (18, 27, 'R_T'),\n",
       "    (160, 170, 'R_T'),\n",
       "    (201, 203, 'R_T'),\n",
       "    (62, 64, 'R_T')]}),\n",
       " ('orr before and after the switch to q2w will be summarized .',\n",
       "  {'entities': [(47, 57, 'R_T')]}),\n",
       " ('the frequency ( number and percentage ) of participant with bor by investigator in each response category will be summarized : crr by bicr and crr by investigator will be summarized separately .',\n",
       "  {'entities': [(16, 37, 'R_T'), (114, 124, 'R_T'), (4, 13, 'R_T')]}),\n",
       " ('kaplan-meier estimate ( product-limit estimate ) will be presented and displayed graphically where appropriate , together with a summary of associated statistic including the median pfs time with 2-sided 95 % ci the ci for the median will be calculated .',\n",
       "  {'entities': [(204, 211, 'R_T'),\n",
       "    (175, 181, 'R_T'),\n",
       "    (242, 252, 'R_T'),\n",
       "    (151, 160, 'R_T'),\n",
       "    (129, 136, 'R_T'),\n",
       "    (13, 21, 'R_T'),\n",
       "    (144, 146, 'R_T'),\n",
       "    (81, 92, 'R_F')]}),\n",
       " ('frequency ( number and percentage ) of participant with each event type ( pd or death ) and censoring reason will be presented along with the overall event and censor rate .',\n",
       "  {'entities': [(12, 33, 'R_T'), (0, 9, 'R_T')]}),\n",
       " ('reason for censoring will be summarized according to the category in table 5 .',\n",
       "  {'entities': [(69, 74, 'R_T'), (29, 39, 'R_T')]}),\n",
       " ('pfs by bicr and pfs by investigator will be summarized separately .',\n",
       "  {'entities': [(44, 54, 'R_T')]}),\n",
       " ('if at least 3 participant achieve an objective response and subsequently have an event , dor will be estimated using the same kaplan-meier method a described for pfs in and displayed graphically where appropriate .',\n",
       "  {'entities': [(183, 194, 'R_F')]}),\n",
       " ('in addition , duration of response follow-up from initial dose and initial response will be summarized with simple descriptive statistic and a swimmer plot for dor may also be produced .',\n",
       "  {'entities': [(127, 136, 'R_T'), (151, 155, 'R_F'), (92, 102, 'R_T')]}),\n",
       " ('dor by bicr and dor by investigator will be summarized separately .',\n",
       "  {'entities': [(44, 54, 'R_T')]}),\n",
       " ('if at least 3 participant achieve a scr/cr and subsequently have an event , docr will be estimated using the same kaplan-meier method a described for dor in section 6.2.5 and displayed graphically where appropriate .',\n",
       "  {'entities': [(185, 196, 'R_F')]}),\n",
       " ('o time will be estimated using the same kaplan-meier method and displayed graphically a described for pfs in section 6.2.4 .',\n",
       "  {'entities': [(74, 85, 'R_F')]}),\n",
       " ('median o and 2-sided 95 % ci will be provided .',\n",
       "  {'entities': [(0, 6, 'R_T'), (21, 28, 'R_T')]}),\n",
       " ('in addition , duration of follow-up time will be summarized with simple descriptive statistic , a well a with reverse kaplan-meier method .',\n",
       "  {'entities': [(84, 93, 'R_T'), (49, 59, 'R_T')]}),\n",
       " ('ttr , ttvgpr , and ttcr will be summarized using simple descriptive statistic .',\n",
       "  {'entities': [(32, 42, 'R_T'), (68, 77, 'R_T')]}),\n",
       " ('summary statistic will be provided for pre-dose and post-dose elranatamab concentration at scheduled visit and nominal timepoints .',\n",
       "  {'entities': [(0, 7, 'R_T'), (8, 17, 'R_T')]}),\n",
       " ('value below the limit of quantitation will be treated a zero in the descriptive statistic calculation .',\n",
       "  {'entities': [(80, 89, 'R_T')]}),\n",
       " ('the summary table will include the number of participant , number of sample with blq value , mean , standard deviation , percent coefficient of variation ( % cv ) , median , minimum , maximum , geometric mean , and geometric % cv .',\n",
       "  {'entities': [(174, 181, 'R_T'),\n",
       "    (194, 208, 'R_T'),\n",
       "    (4, 17, 'R_T'),\n",
       "    (100, 118, 'R_T'),\n",
       "    (184, 191, 'R_T'),\n",
       "    (69, 75, 'R_T'),\n",
       "    (165, 171, 'R_T'),\n",
       "    (93, 97, 'R_T'),\n",
       "    (158, 160, 'R_T'),\n",
       "    (129, 153, 'R_T')]}),\n",
       " ('the box and whisker plot will be overlaid with geometric mean .',\n",
       "  {'entities': [(4, 24, 'R_F'), (47, 61, 'R_T')]}),\n",
       " ('the percentage of participant with positive ada will be summarized .',\n",
       "  {'entities': [(4, 14, 'R_T'), (56, 66, 'R_T')]}),\n",
       " ('listing and summary tabulation of the ada data at baseline and post-baseline will be generated .',\n",
       "  {'entities': [(12, 19, 'R_T'), (0, 7, 'R_L')]}),\n",
       " ('sample may also be analyzed for the presence of neutralizing antibody ( nab ) , and any data will be similarly summarized .',\n",
       "  {'entities': [(0, 6, 'R_T'), (111, 121, 'R_T')]}),\n",
       " ('for each cohort at each time point , the number and percentage of participant who completed these instrument will be summarized , a will the reason for non-completion of these measure .',\n",
       "  {'entities': [(41, 62, 'R_T'), (117, 127, 'R_T')]}),\n",
       " ('for each of the 15 scale , the result will be summarized using descriptive statistic including mean , standard deviation , 95 % ci , median , minimum , maximum at each timepoint .',\n",
       "  {'entities': [(95, 99, 'R_T'),\n",
       "    (46, 56, 'R_T'),\n",
       "    (142, 149, 'R_T'),\n",
       "    (102, 120, 'R_T'),\n",
       "    (152, 159, 'R_T'),\n",
       "    (75, 84, 'R_T'),\n",
       "    (133, 139, 'R_T'),\n",
       "    (123, 130, 'R_T')]}),\n",
       " ('a with the qlq-c30 , the analysis of the qlq-my20 scale will be summarized using descriptive statistic including mean , standard deviation , 95 % ci , median , minimum , maximum at each timepoint .',\n",
       "  {'entities': [(160, 167, 'R_T'),\n",
       "    (151, 157, 'R_T'),\n",
       "    (64, 74, 'R_T'),\n",
       "    (93, 102, 'R_T'),\n",
       "    (120, 138, 'R_T'),\n",
       "    (170, 177, 'R_T'),\n",
       "    (113, 117, 'R_T'),\n",
       "    (141, 148, 'R_T')]}),\n",
       " ('number and percent will be summarized for the item-level response at each visit .',\n",
       "  {'entities': [(27, 37, 'R_T')]}),\n",
       " ('the analysis of the qlq-cipn20 subscales will consist of descriptive statistic based on observed value and change from baseline value .',\n",
       "  {'entities': [(69, 78, 'R_T')]}),\n",
       " ('analysis of the eq-5d index will consist of descriptive statistic based on observed value and , separately , based on change from baseline .',\n",
       "  {'entities': [(56, 65, 'R_T')]}),\n",
       " ('analysis of eq-vas will consist of descriptive statistic based on observed value and separately , based on change from baseline .',\n",
       "  {'entities': [(47, 56, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('study conduct and subject disposition the number and percentage of subject in the safety analysis set , completing the study , prematurely discontinuing the study , and the reason for subject discontinuation , will be summarized .',\n",
       "  {'entities': [(218, 228, 'R_T'), (42, 63, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]}),\n",
       " ('the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .',\n",
       "  {'entities': [(158, 167, 'R_T'),\n",
       "    (16, 37, 'R_T'),\n",
       "    (91, 93, 'R_T'),\n",
       "    (4, 13, 'R_T')]})]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "training_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "train,valid = train_test_split(training_data ,\n",
    "                                   random_state=104, \n",
    "                                   test_size=0.30, \n",
    "                                   shuffle=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "359"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(train)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "155"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(valid)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# lists = [('They will be summarized using the on-study approach as defined in Section 3.5.1. The ontreatment+ 28-day approach will only be presented as a flag in listings.',{'entities':[(150, 158, 'R_L')]}),('Pre-dose (trough) PK concentrations will be listed using PK concentration set.',{'entities': [(44, 50, 'R_L')]}),('Laboratory test values for individual subjects will be listed.',{'entities': [(55, 61, 'R_L')]}),('All laboratory data listing and summary will be based on safety analysis set using the on-treatment+5-day approach.',{'entities': [(20, 27, 'R_L'),(32, 39, 'R_T')]}),('Deviations from the nominal time will be given in a separate listing.',{'entities': [(61, 68, 'R_L')]}),('a listing of all urine concentrations over each time interval sorted by group, subject ID and nominal collection duration postdose.',{'enities': [(2, 9, 'R_L')]}),('All prior and concomitant medication(s) as well as non-drug treatment(s) will be provided in listings.',{'entities': [(93, 100, 'R_L')]}),('Participant data listings for demography and baseline characteristics data will also be generated.',{'entities': [(17, 25, 'R_L')]}),('Participant data listings for demography and other infant data will also be generated.',{'entities': [(17, 25, 'R_L')]}),('The protocol deviations listings will be generated separately for maternal and infant participants.',{'entities': [(24, 32, 'R_L')]}),('Listings of participants reporting any AE and immediate AEs, and listings of all reported AEs will be generated.',{'entities': [(0, 8, 'R_L')]}),('Also, separate listings for participants with abnormal laboratory results will be generated.',{'entities': [(15, 23, 'R_L')]}),('Descriptive summaries (counts and percentages) and listings based on the safety population will be provided in accordance with the Pfizer reporting standards.',{'entities': [(51, 59, 'R_L'), (12, 21, 'R_T')]}),('The summaries and listings for these data will be generated only for maternal participants.',{'entities': [(4, 13, 'R_T'), (18, 26, 'R_L')]})]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# valid=valid+lists"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'R_T': 671, 'R_F': 41, 'R_L': 52}\n"
     ]
    }
   ],
   "source": [
    "def count_labels(dataset, labels):\n",
    "    label_counts = {label: 0 for label in labels}\n",
    "    for _, annotations in dataset:\n",
    "        for _, _, label in annotations['entities']:\n",
    "            if label in label_counts:\n",
    "                label_counts[label] += 1\n",
    "    return label_counts\n",
    "\n",
    " \n",
    "\n",
    "labels_to_count = ['R_T', 'R_F', 'R_L']\n",
    "label_counts = count_labels(train, labels_to_count)\n",
    "\n",
    " \n",
    "\n",
    "print(label_counts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "#pip install imbalanced-learn"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "import random\n",
    "\n",
    "def balance_data(training_data):\n",
    "    # Count the frequency of each label\n",
    "    label_counts = defaultdict(list)\n",
    "    for sentence, annotations in training_data:\n",
    "        for _, _, label in annotations['entities']:\n",
    "            label_counts[label].append((sentence, annotations['entities']))\n",
    "\n",
    "    # Find the label with the maximum frequency\n",
    "    max_count = max(len(annotations_list) for annotations_list in label_counts.values())\n",
    "    min_count = min(len(annotations_list) for annotations_list in label_counts.values())\n",
    "\n",
    "    # Determine the target count for oversampling\n",
    "    target_count = min_count + (max_count - min_count) // 2\n",
    "\n",
    "    # Create a balanced training set\n",
    "    balanced_data = []\n",
    "    for label, annotations_list in label_counts.items():\n",
    "        if len(annotations_list) == max_count:\n",
    "            # Undersample the majority class to the target count\n",
    "            undersampled_annotations = random.sample(annotations_list, target_count)\n",
    "            balanced_data.extend(undersampled_annotations)\n",
    "        else:\n",
    "            # Oversample the minority classes to the target count\n",
    "            oversampled_annotations = random.choices(annotations_list, k=target_count - len(annotations_list))\n",
    "            balanced_data.extend(annotations_list + oversampled_annotations)\n",
    "\n",
    "    balanced_training_data = [(sentence, {'entities': annotations}) for sentence, annotations in balanced_data]\n",
    "    return balanced_training_data\n",
    "\n",
    "balanced_training_data = balance_data(training_data)\n",
    "#print(balanced_training_data)\n",
    "\n",
    "  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'R_T': 2904, 'R_F': 770, 'R_L': 597}\n"
     ]
    }
   ],
   "source": [
    "def count_labels(dataset, labels):\n",
    "    label_counts = {label: 0 for label in labels}\n",
    "    for _, annotations in dataset:\n",
    "        for _, _, label in annotations['entities']:\n",
    "            if label in label_counts:\n",
    "                label_counts[label] += 1\n",
    "    return label_counts\n",
    "\n",
    " \n",
    "\n",
    "labels_to_count = ['R_T', 'R_F', 'R_L']\n",
    "label_counts = count_labels(balanced_training_data, labels_to_count)\n",
    "\n",
    " \n",
    "\n",
    "print(label_counts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from __future__ import unicode_literals, print_function\n",
    "\n",
    "import random\n",
    "from pathlib import Path\n",
    "import spacy\n",
    "from tqdm import tqdm\n",
    "from spacy.training.example import Example\n",
    "import pickle"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "model = None\n",
    "output_dir=Path(\"ner/\")\n",
    "n_iter=10\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Created blank 'en' model\n"
     ]
    }
   ],
   "source": [
    "\n",
    "#load the model\n",
    "\n",
    "if model is not None:\n",
    "    nlp = spacy.load(model)  \n",
    "    print(\"Loaded model '%s'\" % model)\n",
    "else:\n",
    "    nlp = spacy.blank('en')  \n",
    "    print(\"Created blank 'en' model\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "#set up the pipeline\n",
    "\n",
    "if 'ner' not in nlp.pipe_names:\n",
    "    ner = nlp.add_pipe('ner')\n",
    "    #nlp.add_pipe(ner, last=True)\n",
    "else:\n",
    "    ner = nlp.get_pipe('ner')\n",
    "# adding labels to ner\n",
    "for _, annotations in balanced_training_data:\n",
    "    for ent in annotations.get('entities'):\n",
    "        ner.add_label(ent[2])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  1%|          | 11/1503 [00:00<01:18, 18.93it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"kaplan-meier estimate ( product-limit estimate ) w...\" with entities \"[(204, 211, 'R_T'), (175, 181, 'R_T'), (242, 252, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  2%|▏         | 30/1503 [00:02<02:35,  9.46it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"kaplan-meier estimate ( product-limit estimate ) w...\" with entities \"[(176, 183, 'R_T'), (122, 131, 'R_T'), (115, 117, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  2%|▏         | 32/1503 [00:02<02:12, 11.09it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"safety endpoint based on the safety analysis set ,...\" with entities \"[(571, 578, 'R_L'), (8, 9, 'R_T'), (160, 170, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  3%|▎         | 46/1503 [00:03<01:59, 12.24it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"annualized total factor consumption of moroctocog ...\" with entities \"[(110, 116, 'R_T'), (209, 215, 'R_T'), (169, 178, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  4%|▎         | 55/1503 [00:04<01:20, 18.09it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for aes classified a tier2 event , difference in p...\" with entities \"[(83, 90, 'R_T'), (68, 70, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  4%|▍         | 59/1503 [00:04<01:16, 18.93it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"baseline summary thefollowingdemographic andbaseli...\" with entities \"[(2014, 2020, 'R_T'), (6, 7, 'R_T'), (435, 438, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  4%|▍         | 63/1503 [00:04<01:34, 15.17it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"total event discrepancy rate ( b+c ) /n , early di...\" with entities \"[(9, 10, 'R_T'), (189, 199, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  6%|▌         | 88/1503 [00:05<00:55, 25.41it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"extent of exposure to study intervention will be s...\" with entities \"[(143, 152, 'R_T'), (97, 103, 'R_T'), (74, 83, 'R_...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  6%|▌         | 91/1503 [00:05<00:57, 24.56it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"the seroprotection rate before vaccination 2 and 1...\" with entities \"[(190, 200, 'R_T'), (170, 180, 'R_T'), (17, 18, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  8%|▊         | 124/1503 [00:07<00:59, 23.21it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"in addition , all protocol deviation related to co...\" with entities \"[(80, 96, 'R_L')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  8%|▊         | 127/1503 [00:07<00:57, 23.95it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"pharmacokinetic parameter for avelumab and talazop...\" with entities \"[(236, 243, 'R_T'), (10, 11, 'R_T'), (161, 167, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "  9%|▉         | 136/1503 [00:07<00:53, 25.49it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"additionally , all fold rise specified will be sum...\" with entities \"[(92, 99, 'R_T'), (47, 57, 'R_T'), (32, 34, 'R_T')...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 10%|▉         | 145/1503 [00:08<00:55, 24.39it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for the primary study cohort - stage 1 , the serop...\" with entities \"[(58, 59, 'R_T'), (231, 241, 'R_T'), (262, 269, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 12%|█▏        | 175/1503 [00:09<00:54, 24.25it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"medication will be coded using the who drug coding...\" with entities \"[(74, 83, 'R_T'), (125, 134, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 13%|█▎        | 199/1503 [00:10<00:52, 24.94it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"3 event immediately after missing at least two eve...\" with entities \"[(644, 650, 'R_T'), (674, 682, 'R_T'), (167, 180, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 14%|█▎        | 205/1503 [00:10<01:03, 20.41it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \" kaplan-meier estimate ( time-to-event distirbuti...\" with entities \"[(88, 99, 'R_F'), (151, 153, 'R_T'), (136, 143, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 15%|█▌        | 226/1503 [00:11<00:52, 24.43it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"kaplan-meier estimate ( product-limit estimate ) w...\" with entities \"[(204, 211, 'R_T'), (175, 181, 'R_T'), (151, 160, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 15%|█▌        | 229/1503 [00:11<00:58, 21.83it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"gmt of the rsv a–and rsv b–neutralizing antibody t...\" with entities \"[(172, 179, 'R_T'), (129, 131, 'R_T'), (92, 116, '...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 16%|█▌        | 234/1503 [00:12<01:18, 16.08it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"kaplan-meier estimate will be presented together w...\" with entities \"[(102, 108, 'R_T'), (71, 73, 'R_T'), (56, 63, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 16%|█▌        | 238/1503 [00:12<01:26, 14.58it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for the primary study cohort - stage 2 , gmt befor...\" with entities \"[(198, 205, 'R_T'), (149, 173, 'R_T'), (73, 75, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 17%|█▋        | 256/1503 [00:14<01:27, 14.31it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"gmt before and 1 month after vaccination 1 , and a...\" with entities \"[(68, 75, 'R_T'), (86, 96, 'R_T'), (32, 34, 'R_T')...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 18%|█▊        | 268/1503 [00:14<01:18, 15.76it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for each cohort , the igg a and igg b will be desc...\" with entities \"[(46, 70, 'R_T'), (103, 110, 'R_T'), (88, 90, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 22%|██▏       | 338/1503 [00:19<01:00, 19.22it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"similarly , for the rsv vaccine month-0 , month-2 ...\" with entities \"[(95, 105, 'R_T'), (27, 29, 'R_T'), (119, 126, 'R_...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 24%|██▎       | 355/1503 [00:20<01:02, 18.37it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"also , gmfrs from before to 1 month after vaccinat...\" with entities \"[(99, 109, 'R_T'), (81, 88, 'R_T'), (45, 47, 'R_T'...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 26%|██▌       | 389/1503 [00:22<01:03, 17.62it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"in addition , the frequency ( number and percentag...\" with entities \"[(144, 151, 'R_T'), (30, 51, 'R_T'), (18, 27, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 32%|███▏      | 482/1503 [00:29<01:17, 13.22it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"also , gmfrs from before to 1 month after vaccinat...\" with entities \"[(95, 105, 'R_T'), (79, 86, 'R_T'), (45, 47, 'R_T'...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 34%|███▍      | 515/1503 [00:32<02:09,  7.66it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"similarly , for each cohort , the fold rise of igg...\" with entities \"[(158, 165, 'R_T'), (143, 145, 'R_T'), (100, 124, ...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 37%|███▋      | 553/1503 [00:36<01:18, 12.17it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"the following subgroup will be analyzed :  baseli...\" with entities \"[(11, 12, 'R_T'), (310, 312, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 42%|████▏     | 632/1503 [00:42<01:12, 12.05it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"summarystatisticswill beprovidedforplasmaconcentra...\" with entities \"[(43, 44, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 48%|████▊     | 726/1503 [00:50<00:52, 14.68it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"the stratified hazard ratio ( talazoparib in combi...\" with entities \"[(104, 111, 'R_T'), (22, 27, 'R_T'), (97, 99, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 52%|█████▏    | 784/1503 [00:55<00:55, 12.96it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for the primary study cohort - stage 1 , gmt at al...\" with entities \"[(169, 176, 'R_T'), (84, 86, 'R_T'), (128, 138, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 59%|█████▉    | 893/1503 [01:06<01:36,  6.34it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"study/treatment exposure extent of exposure to stu...\" with entities \"[(97, 106, 'R_T'), (120, 126, 'R_T'), (129, 147, '...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 70%|██████▉   | 1045/1503 [01:23<00:46,  9.76it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"for each cohort , the endpoint defined in will be ...\" with entities \"[(23, 24, 'R_T'), (101, 108, 'R_T'), (70, 80, 'R_T...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 72%|███████▏  | 1084/1503 [01:27<00:47,  8.80it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"a summary of duration ( day ) of dosinginterruptio...\" with entities \"[(2, 9, 'R_T'), (20, 21, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 77%|███████▋  | 1152/1503 [01:35<00:28, 12.52it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"the proportion of infant participant with lrti cau...\" with entities \"[(146, 153, 'R_T'), (30, 32, 'R_T'), (197, 207, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 77%|███████▋  | 1160/1503 [01:35<00:28, 11.87it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"kaplan-meier estimate will be presented by treatme...\" with entities \"[(64, 71, 'R_T'), (110, 116, 'R_T'), (134, 141, 'R...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 87%|████████▋ | 1315/1503 [01:58<00:36,  5.13it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"protocol deviation important protocol deviation wi...\" with entities \"[(103, 113, 'R_T'), (17, 18, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      " 96%|█████████▌| 1441/1503 [02:16<00:08,  7.71it/s]C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"risk difference of pooled lotiglipronvs placebo wi...\" with entities \"[(201, 213, 'R_T'), (66, 74, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "100%|██████████| 1503/1503 [02:23<00:00, 10.51it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 3812.2998677915884}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [02:12<00:00, 11.32it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 1772.2125953118189}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [02:11<00:00, 11.40it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 1303.7158064406456}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [02:01<00:00, 12.40it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 1171.3327027447626}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:54<00:00, 13.18it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 1095.4758077549182}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:46<00:00, 14.16it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 911.6827471697046}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:26<00:00, 17.46it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 780.0491721952683}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:22<00:00, 18.26it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 708.1909437096365}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:22<00:00, 18.13it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 713.9284035145153}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1503/1503 [01:23<00:00, 18.06it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 637.1991262765455}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "example = []\n",
    "other_pipes = [pipe for pipe in nlp.pipe_names if pipe != 'ner']\n",
    "with nlp.disable_pipes(*other_pipes):  # only train NER\n",
    "    optimizer = nlp.begin_training()\n",
    "    for itn in range(n_iter):\n",
    "        random.shuffle(balanced_training_data)\n",
    "        losses = {}\n",
    "        for text, annotations in tqdm(balanced_training_data):\n",
    "            doc = nlp.make_doc(text)\n",
    "            example = Example.from_dict(doc, annotations)\n",
    "            nlp.update(\n",
    "                [example], \n",
    "                drop=0.5,  \n",
    "                sgd=optimizer,\n",
    "                losses=losses)\n",
    "        print(losses)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "lists=[('They will be summarized using the on-study approach as defined in Section 3.5.1. The ontreatment+ 28-day approach will only be presented as a flag in listings.',{'entities':[(150, 158, 'R_L')]}),\n",
    "       ('Pre-dose (trough) PK concentrations will be listed using PK concentration set.',{'entities': [(44, 50, 'R_L')]}),\n",
    "       ('Laboratory test values for individual subjects will be listed.',{'entities': [(55, 61, 'R_L')]}),\n",
    "       ('All laboratory data listing and summary will be based on safety analysis set using the on-treatment+5-day approach.',{'entities': [(20, 27, 'R_L'),(32, 39, 'R_T')]}),\n",
    "       ('Deviations from the nominal time will be given in a separate listing.',{'entities': [(61, 68, 'R_L')]}),\n",
    "       ('a listing of all urine concentrations over each time interval sorted by group, subject ID and nominal collection duration postdose.',{'entities': [(2, 9, 'R_L')]}),\n",
    "        ('All prior and concomitant medication(s) as well as non-drug treatment(s) will be provided in listings.',{'entities': [(93, 100, 'R_L')]}),\n",
    "        ('Participant data listings for demography and baseline characteristics data will also be generated.',{'entities': [(17, 25, 'R_L')]}),\n",
    "       ('Participant data listings for demography and other infant data will also be generated.',{'entities': [(17, 25, 'R_L')]}),\n",
    "        ('The protocol deviations listings will be generated separately for maternal and infant participants.',{'entities': [(24, 32, 'R_L')]}),\n",
    "       ('Listings of participants reporting any AE and immediate AEs, and listings of all reported AEs will be generated.',{'entities': [(0, 8, 'R_L')]}),\n",
    "         ('Also, separate listings for participants with abnormal laboratory results will be generated.',{'entities': [(15, 23, 'R_L')]}),\n",
    "         ('Descriptive summaries (counts and percentages) and listings based on the safety population will be provided in accordance with the Pfizer reporting standards.',{'entities': [(51, 59, 'R_L'), (12, 21, 'R_T')]}),\n",
    "         ('The summaries and listings for these data will be generated only for maternal participants.',{'entities': [(4, 13, 'R_T'), (18, 26, 'R_L')]})]\n",
    "       "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "valid_ls=valid+lists"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"gmt before and 1 month after vaccination 1 and ass...\" with entities \"[(66, 73, 'R_T'), (32, 34, 'R_T'), (82, 92, 'R_T')...\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \" the tipping point analysis ( section 5.3.1 ) wil...\" with entities \"[(224, 229, 'R_T'), (550, 562, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \" analysis methodology :  time to first occurrenc...\" with entities \"[(230, 244, 'R_T'), (3, 4, 'R_T')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n",
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\training\\iob_utils.py:152: UserWarning: [W030] Some entities could not be aligned in the text \"All prior and concomitant medication(s) as well as...\" with entities \"[(93, 100, 'R_L')]\". Use `spacy.training.offsets_to_biluo_tags(nlp.make_doc(text), entities)` to check the alignment. Misaligned entities ('-') will be ignored during training.\n",
      "  entities=ent_str[:50] + \"...\" if len(ent_str) > 50 else ent_str,\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'token_acc': 1.0, 'token_p': 1.0, 'token_r': 1.0, 'token_f': 1.0, 'ents_p': 0.9326923076923077, 'ents_r': 0.9208860759493671, 'ents_f': 0.9267515923566879, 'ents_per_type': {'R_T': {'p': 0.9315589353612167, 'r': 0.9386973180076629, 'f': 0.9351145038167938}, 'R_F': {'p': 0.8235294117647058, 'r': 0.9333333333333333, 'f': 0.8749999999999999}, 'R_L': {'p': 1.0, 'r': 0.8, 'f': 0.888888888888889}}, 'speed': 21547.82776874868}\n"
     ]
    }
   ],
   "source": [
    "examples = []\n",
    "\n",
    "for text, annots in valid_ls:\n",
    "    doc = nlp.make_doc(text)\n",
    "    examples.append(Example.from_dict(doc, annots))\n",
    "print(nlp.evaluate(examples))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Saved model to ner\n"
     ]
    }
   ],
   "source": [
    "if output_dir is not None:\n",
    "    output_dir = Path(output_dir)\n",
    "    if not output_dir.exists():\n",
    "        output_dir.mkdir()\n",
    "    nlp.to_disk(output_dir)\n",
    "    print(\"Saved model to\", output_dir)\n",
    "pickle.dump(nlp, open( \"ner_nlp_Model_2.pkl\", \"wb\" ))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "text=\"Descriptive statistics (number and frequency) will be provided for all adverse event summaries.\"\n",
    "word_list = nltk.word_tokenize(text)\n",
    "lem_line= ' '.join([lemmatizer.lemmatize(w.lower()) for w in word_list])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "descriptive statistic ( number and frequency ) will be provided for all adverse event summary .\n",
      "R_T  ------>   statistic\n",
      "R_T  ------>   number and frequency\n",
      "R_T  ------>   summary\n"
     ]
    }
   ],
   "source": [
    "doc=nlp(lem_line)\n",
    "print(doc)\n",
    "for ent in doc.ents:\n",
    "    print(ent.label_+ '  ------>   ' + ent.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "#text=\"Bar charts with the proportions of subjects reporting each systemic event within 14 days after vaccination will be plotted for each vaccine group. The bars will be stacked by maximum severity to highlight the proportions of subjects by severity.\"\n",
    "text=\"The number and percentage of subject with at least 1 diagnosis , overall and at each SOC and PTlevel , maybe summarized by vaccine group and for overall subject included in the safety population for each cohort\"\n",
    "word_list = nltk.word_tokenize(text)\n",
    "lem_line= ' '.join([lemmatizer.lemmatize(w.lower()) for w in word_list])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "the number and percentage of subject with at least 1 diagnosis , overall and at each soc and ptlevel , maybe summarized by vaccine group and for overall subject included in the safety population for each cohort\n",
      "R_T  ------>   number and percentage\n",
      "R_T  ------>   summarized\n"
     ]
    }
   ],
   "source": [
    "doc=nlp(lem_line)\n",
    "print(doc)\n",
    "for ent in doc.ents:\n",
    "    print(ent.label_+ '  ------>   ' + ent.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "text= ['Descriptive statistics (number and frequency) will be provided for all adverse event summaries.'\n",
    "        'following demographic and baseline characteristics will be summary by number',\n",
    "        'The number and proportion of participants experiencing DLTs during the DLT-evaluation period specific to the DLTs will be summarized by SOC and PT based on maximum toxicity grade by dose cohort. Analyses of DLT will be performed on DLT Evaluable Set. ',\n",
    "        'A listing of elranatamab, iberdomide concentrations by study visit and timepoint will be generated.',\n",
    "        'Bar charts with the proportions of subjects reporting each systemic event within 14 days after vaccination will be plotted for each vaccine group. The bars will be stacked by maximum severity to highlight the proportions of subjects by severity.',\n",
    "        'The percentage of participants with positive ADA will be summarized.',\n",
    "       ' Listings and summary tabulations of the ADA data at baseline and post-baseline will be generated.',\n",
    "      'Figures : Bar chart with the proportion of subject reporting each AE category after vaccination will be plotted for each vaccine']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Descriptive statistics (number and frequency) will be provided for all adverse event summaries.following demographic and baseline characteristics will be summary by number \n",
      "\n",
      "Descriptive statistics (number and frequency) will be provided for all adverse event summaries.following demographic and baseline characteristics will be summary by number\n",
      "R_T  ------>   statistic\n",
      "R_T  ------>   number and frequency\n",
      "R_T  ------>   summary\n",
      "The number and proportion of participants experiencing DLTs during the DLT-evaluation period specific to the DLTs will be summarized by SOC and PT based on maximum toxicity grade by dose cohort. \n",
      "\n",
      "The number and proportion of participants experiencing DLTs during the DLT-evaluation period specific to the DLTs will be summarized by SOC and PT based on maximum toxicity grade by dose cohort.\n",
      "R_T  ------>   number and proportion\n",
      "R_T  ------>   summarized\n",
      "R_T  ------>   maximum\n",
      "Analyses of DLT will be performed on DLT Evaluable Set. \n",
      "\n",
      "Analyses of DLT will be performed on DLT Evaluable Set.\n",
      "A listing of elranatamab, iberdomide concentrations by study visit and timepoint will be generated. \n",
      "\n",
      "A listing of elranatamab, iberdomide concentrations by study visit and timepoint will be generated.\n",
      "R_L  ------>   listing\n",
      "Bar charts with the proportions of subjects reporting each systemic event within 14 days after vaccination will be plotted for each vaccine group. \n",
      "\n",
      "Bar charts with the proportions of subjects reporting each systemic event within 14 days after vaccination will be plotted for each vaccine group.\n",
      "R_F  ------>   Bar chart\n",
      "R_F  ------>   plotted\n",
      "The bars will be stacked by maximum severity to highlight the proportions of subjects by severity. \n",
      "\n",
      "The bars will be stacked by maximum severity to highlight the proportions of subjects by severity.\n",
      "R_F  ------>   bar will be stacked by\n",
      "R_T  ------>   maximum\n",
      "The percentage of participants with positive ADA will be summarized. \n",
      "\n",
      "The percentage of participants with positive ADA will be summarized.\n",
      "R_T  ------>   percentage\n",
      "R_T  ------>   summarized\n",
      " Listings and summary tabulations of the ADA data at baseline and post-baseline will be generated. \n",
      "\n",
      " Listings and summary tabulations of the ADA data at baseline and post-baseline will be generated.\n",
      "R_T  ------>   summary\n",
      "Figures : Bar chart with the proportion of subject reporting each AE category after vaccination will be plotted for each vaccine \n",
      "\n",
      "Figures : Bar chart with the proportion of subject reporting each AE category after vaccination will be plotted for each vaccine\n",
      "R_F  ------>   Figures\n",
      "R_F  ------>   Bar chart\n",
      "R_F  ------>   plotted\n"
     ]
    }
   ],
   "source": [
    "for each in text:\n",
    "    sentence = sent_tokenize(each)\n",
    "    for sen in sentence:\n",
    "        print(sen,'\\n')\n",
    "        word_list = nltk.word_tokenize(sen)\n",
    "        lem_line= ' '.join([lemmatizer.lemmatize(w) for w in word_list])\n",
    "        doc=nlp(lem_line)\n",
    "        print(sen)\n",
    "        for ent in doc.ents:\n",
    "            print(ent.label_+ '  ------>   ' + ent.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">descriptive \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    statistic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " ( \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    number and frequency\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " ) will be provided for all adverse event summaries.following demographic and baseline characteristic will be \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " by number</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    number and proportion\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " of participant experiencing dlts during the dlt-evaluation period specific to the dlts will be \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summarized\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " by soc and pt based on \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    maximum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " toxicity grade by dose cohort .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\displacy\\__init__.py:213: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  warnings.warn(Warnings.W006)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">analysis of dlt will be performed on dlt evaluable set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " of elranatamab , iberdomide concentration by study visit and timepoint will be generated .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bar chart\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " with the proportion of subject reporting each systemic event within 14 day after vaccination will be \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plotted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " for each vaccine group .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bar will be stacked by\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    maximum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " severity to highlight the proportion of subject by severity .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    percentage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " of participant with positive ada will be \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summarized\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " tabulation of the ada data at baseline and post-baseline will be generated .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    figure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " : \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bar chart\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " with the proportion of subject reporting each ae category after vaccination will be \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plotted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " for each vaccine</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for each in text:\n",
    "    sentence = sent_tokenize(each)\n",
    "    for sen in sentence:\n",
    "        word_list = nltk.word_tokenize(sen)\n",
    "        lem_line= ' '.join([lemmatizer.lemmatize(w.lower()) for w in word_list])\n",
    "        doc=nlp(lem_line)\n",
    "        color={'R_T':'pink', 'R_L':'cyan', 'R_F':'violet'}\n",
    "        options={'ents':['R_T','R_L','R_F'],'colors':color}\n",
    "        spacy.displacy.render(doc,style='ent',jupyter=True,options=options)\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
